0001564590-21-050422 | 10-Q | XBRL Viewer

Print Document View Excel Document

Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Aug. 31, 2021	Oct. 04, 2021
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Aug. 31, 2021
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q1
Trading Symbol	TLRY
Entity Registrant Name	TILRAY, INC.
Entity Central Index Key	0001731348
Current Fiscal Year End Date	--05-31
Entity Filer Category	Large Accelerated Filer
Entity Current Reporting Status	Yes
Entity Emerging Growth Company	false
Entity Small Business	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		460,658,653
Title of 12(b) Security	Class 2 Common Stock, $0.0001 par value per share
Entity File Number	001-38594
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	82-4310622
Entity Interactive Data Current	Yes
Security Exchange Name	NASDAQ
Entity Address, Address Line One	655 Madison Avenue
Entity Address, Address Line Two	Suite 1900
Entity Address, City or Town	New York
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	10065
City Area Code	844
Local Phone Number	845-7291
Entity Bankruptcy Proceedings, Reporting Current	true
Document Quarterly Report	true
Document Transition Report	false

Consolidated Statements of Financial Position - USD ($) $ in Thousands	Aug. 31, 2021	May 31, 2021
Current assets
Cash and cash equivalents	$ 376,297	$ 488,466
Accounts receivable, net	97,177	87,309
Inventory	251,507	256,429
Prepaids and other current assets	117,267	48,920
Convertible notes receivable	2,370	2,485
Total current assets	844,618	883,609
Capital assets	621,339	650,698
Right-of-use assets	17,783	18,267
Intangible assets	1,502,814	1,605,918
Goodwill	2,809,131	2,832,794
Interest in equity investees	4,062	8,106
Long-term investments	186,407	17,685
Other assets	198	8,285
Total assets	5,986,352	6,025,362
Current liabilities
Bank indebtedness	9,203	8,717
Accounts payable and accrued liabilities	190,213	212,813
Contingent consideration	61,494	60,657
Warrant liability	60,476	78,168
Escrow payable	170,799
Current portion of lease liabilities	3,808	4,264
Current portion of long-term debt	30,837	36,622
Total current liabilities	526,830	401,241
Long - term liabilities
Lease liabilities	53,331	53,946
Long-term debt	164,911	167,486
Convertible debentures	611,646	667,624
Deferred tax liability	239,373	265,845
Other liabilities	4,505	3,907
Total liabilities	1,600,596	1,560,049
Commitments and contingencies (refer to Note 16)
Shareholders' equity
Common stock	46	46
Additional paid-in capital	4,795,879	4,792,406
Accumulated other comprehensive income	51,247	152,668
Deficit	(527,699)	(486,050)
Total Tilray shareholders' equity	4,319,473	4,459,070
Non-controlling interests	66,283	6,243
Total shareholders' equity	4,385,756	4,465,313
Total liabilities and shareholders' equity	$ 5,986,352	$ 6,025,362

Consolidated Statements of Loss and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Aug. 31, 2021	Aug. 31, 2020
Income Statement [Abstract]
Net revenue	$ 168,023	$ 117,490
Cost of goods sold	117,068	82,545
Gross profit	50,955	34,945
Operating expenses:
General and administrative	49,487	25,972
Selling	7,432	5,817
Amortization	30,739	4,127
Marketing and promotion	5,465	4,925
Research and development	785	120
Transaction costs	25,579	2,458
Total operating expenses	119,487	43,419
Operating loss	(68,532)	(8,474)
Finance expense, net	(10,170)	(5,736)
Non-operating income (expense), net	48,860	(13,359)
Loss before income taxes	(29,842)	(27,569)
Income taxes (recovery)	4,762	(5,825)
Net loss	(34,604)	(21,744)
Total net income (loss) attributable to:
Shareholders of Tilray Inc.	(41,649)	(34,343)
Non-controlling interests	7,045	12,599
Other comprehensive (loss) income, net of tax
Foreign currency translation (loss) gain	(100,772)	1,385
Unrealized loss on convertible notes receivable	(649)
Total other comprehensive (loss) income, net of tax	(101,421)	1,385
Comprehensive loss	(136,025)	(20,359)
Total comprehensive income (loss) attributable to:
Shareholders of Tilray Inc.	(143,070)	(32,958)
Non-controlling interests	$ 7,045	$ 12,599
Weighted average number of common shares - basic	449,397,822	241,992,864
Weighted average number of common shares - diluted	449,397,822	241,992,864
Loss per share - basic	$ (0.08)	$ (0.09)
Loss per share - diluted	$ (0.08)	$ (0.09)

Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Total	LP	Common Stock	Additional Paid-In Capital	Accumulated Other Comprehensive Income (Loss)	Deficit	Non-controlling Interests	Non-controlling Interests LP
Beginning Balance at May. 31, 2020	$ 1,274,931		$ 24	$ 1,366,736	$ (5,434)	$ (113,352)	$ 26,957
Beginning Balance, Shares at May. 31, 2020			240,132,635
Share issuance - legal settlement	7,018			7,018
Share issuance - legal settlement, shares			1,389,884
Share issuance - options exercised	4			4
Share issuance - options exercised, shares			41,065
Share issuance - RSUs exercised	2,246			2,246
Share issuance - RSUs exercised, shares			429,280
Share-based payments, net	1,233			1,233
Comprehensive income (loss) for the period	(20,359)				1,385	(34,343)	12,599
Ending Balance at Aug. 31, 2020	1,265,073		$ 24	1,377,237	(4,049)	(147,695)	39,556
Ending Balance, Shares at Aug. 31, 2020			241,992,864
Beginning Balance at May. 31, 2021	4,465,313		$ 46	4,792,406	152,668	(486,050)	6,243
Beginning Balance, Shares at May. 31, 2021			446,440,641
Third party contribution to acquisition		$ 52,995						$ 52,995
Share issuance - options exercised	2,756			2,756
Share issuance - options exercised, shares			417,489
Share issuance - RSUs exercised	6,661			6,661
Share issuance - RSUs exercised, shares			3,665,337
Share-based payments, net	(5,944)			(5,944)
Comprehensive income (loss) for the period	(136,025)				(101,421)	(41,649)	7,045
Ending Balance at Aug. 31, 2021	$ 4,385,756		$ 46	$ 4,795,879	$ 51,247	$ (527,699)	$ 66,283
Ending Balance, Shares at Aug. 31, 2021			450,523,467

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Aug. 31, 2021	Aug. 31, 2020
Cash used in operating activities:
Net loss	$ (34,604)	$ (21,744)
Adjustments for:
Deferred income tax recovery	(24,873)	(17,984)
Unrealized foreign exchange loss	13,192	15,597
Amortization	39,333	10,979
Loss on sale of capital assets	27
Other non-cash items	165	(67)
Stock-based compensation	4,074	2,850
Loss on long-term investments & equity investments	1,144	1,120
Gain on debt instruments	(57,711)	(340)
Loss on contingent consideration	837
Change in non-cash working capital:
Accounts receivable	(9,868)	(21,656)
Prepaids and other current assets	(7,265)	(6,747)
Inventory	4,922	1,231
Accounts payable and accrued liabilities	(22,600)	(19,339)
Net cash used in operating activities	(93,227)	(56,100)
Cash used in investing activities:
Investment in capital and intangible assets	(16,316)	(13,955)
Proceeds from disposal of capital and intangible assets	7,696
Promissory notes advances		(2,419)
Proceeds from disposal of long-term investments and equity investees		2,676
Net cash used in investing activities	(8,620)	(13,698)
Cash (used in) provided by financing activities:
Share capital issued, net of cash issuance costs		(261)
Proceeds from warrants and options exercised		4
Proceeds from long-term debt		1,887
Repayment of long-term debt	(8,360)	(880)
Repayment of lease liabilities	(154)	31
Increase (decrease) in bank indebtedness	486	5,956
Net cash (used in) provided by financing activities	(8,028)	6,737
Effect of foreign exchange on cash and cash equivalents	(2,294)	9,132
Net decrease in cash and cash equivalents	(112,169)	(53,929)
Cash and cash equivalents, beginning of period	488,466	360,646
Cash and cash equivalents, end of period	$ 376,297	$ 306,717

Description of business

3 Months Ended

Aug. 31, 2021

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Description of business

Note 1. Description of business

Tilray, Inc., and its wholly owned subsidiaries (collectively “Tilray”, the “Company”, “we”, or “us”) is a leading global cannabis-lifestyle and consumer packaged goods company headquartered in Leamington and New York, with operations in Canada, the United States, Europe, Australia, and Latin America that is changing people’s lives for the better – one person at a time – by inspiring and empowering the worldwide community to live their very best life by providing them with products that meet the needs of their mind, body, and soul and invoke a sense of wellbeing. Tilray’s mission is to be the trusted partner for its patients and consumers by providing them with a cultivated experience and health and wellbeing through high-quality, differentiated brands and innovative products. A pioneer in cannabis research, cultivation and distribution, Tilray’s production platform supports over 20 brands in over 20 countries, including comprehensive cannabis offerings, hemp-based foods, and alcoholic beverages.

On April 30, 2021, Tilray acquired all of the issued and outstanding common shares of Aphria Inc. (“Aphria”), an international organization with a focus on building a global cannabis-lifestyle consumer packaged goods company and involved in the manufacturing and distribution of beer and beer derivative products in the United States, and in the distribution of (non-Cannabis) pharmaceutical products in Germany, pursuant to a plan of arrangement (the “Arrangement”) under the Business Corporations Act (Ontario).

Basis of presentation and summary of significant accounting policies

3 Months Ended

Aug. 31, 2021

Accounting Policies [Abstract]

Basis of presentation and summary of significant accounting policies

Note 2. Basis of presentation and summary of significant accounting policies

The accompanying unaudited consolidated financial statements (the “financial statements”) reflect the accounts of the Company. The financial statements were prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) and pursuant to the rules and regulations of the United States Securities and Exchange Commission (“SEC”) for interim financial information. The information included in this Form 10-Q should be read in conjunction with the audited consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended May 31, 2021 (the “Annual Financial Statements”). These financial statements reflect all adjustments, which, in the opinion of management, are necessary for a fair presentation of the results for the interim periods presented. Interim results are not necessarily indicative of results for a full year. The Company’s balance sheet at May 31, 2021 was derived from the audited Annual Financial Statements but does not contain all of the footnote disclosures from the Annual Financial Statements.

These consolidated financial statements have been prepared on the going concern basis which assumes that the Company will continue in operation for the foreseeable future and, accordingly, will be able to realize its assets and discharge its liabilities in the normal course of operations as they come due, under the historical cost convention except for certain financial instruments that are measured at fair value, as detailed in the Company’s accounting policies.

As a result of the April 30, 2021 business combination with Aphria, the reported results do not include the results of operations of Tilray and its subsidiaries on and prior to April 30, 2021, in accordance with the accounting treatment applicable to the Arrangement. Accordingly, comparisons between the Company's first quarter 2022 results and prior periods may not be meaningful.

Information about the accounting treatment of the Arrangement including details of the transaction, determination of the total fair value consideration, and allocation of the purchase price, are included in the Company's Annual Report for the year ended May 31, 2021 filed in Form 10-K with the U.S. Securities and Exchange Commission on July 28, 2021 (“Annual Report”).

The purchase price allocation for the Arrangement is open for adjustments and has been allocated based on estimated fair values of the assets acquired and liabilities assumed at the acquisition date. In the event that more information is obtained, the purchase price allocation may change. Any future adjustments to the purchase price allocation, including changes within identifiable intangible assets or estimation uncertainty impacted by market conditions, may impact future net earnings. The purchase price allocation adjustments can be made through the end of the measurement period, which is not to exceed one year from the acquisition date.

Basis of consolidation

Subsidiaries are entities controlled by the Company. Control exists when the Company either has a controlling voting interest or is the primary beneficiary of a variable interest entity. The financial statements of subsidiaries are included in the consolidated financial statements from the date that control commences until the date that control ceases. A complete list of our subsidiaries that existed prior to our most recent year end is included in the Company's Annual Report for the year ended May 31, 2021 filed in Form 10-K with the U.S. Securities and Exchange Commission on July 28, 2021 (“Annual Report”).

On August 13, 2021, the Company and other investors formed Superhero Acquisition L.P., a Delaware limited partnership, (“SH Acquisition”). SH Acquisition was formed for the purpose of acquiring approximately $165.8 principal amount of senior secured

convertible notes (the “MM Notes”) originally issued by MedMen Enterprises Inc. (“MedMen”) and certain warrants (the “MM Warrants”) to acquire Class B subordinate voting shares of Medmen (the “MedMen Shares”) issued in connection with the original issuance of the MM Notes. The MM Notes mature on August 17, 2028. Pursuant to an Assignment and Assumption Agreement dated as of August 17, 2021, SH Acquisition completed its acquisition (the “MM Transaction”) of the MM Notes and MM Warrants from certain funds affiliated with Gotham Green Partners. As partial consideration for the MM Notes and MM Warrants, on September 17, 2021, the Company issued 9,817,061 shares of its common stock. The balance of the consideration for the MM Notes and MM Warrants was paid in cash by the other partners of SH Acquisition.

The Company’s interest in SH Acquisition represents its right to 68% of the MM Notes and related MM Warrants held by SH Acquisition, which are convertible into approximately 21% of the MedMen Shares outstanding upon closing of the MM Transaction. The Company’s ability to convert the MM Notes and exercise the MM Warrants is dependent upon federal laws in the United States being amended to permit the general cultivation, distribution and possession of cannabis (a “Triggering Event”) or the Company’s waiver of the need for a Triggering Event and the receipt of any additional regulatory approvals.

The Company is a limited partner under the SH Acquisition partnership agreement; however, material events conducted by the partnership require the approval of the Company, and, upon a Triggering Event, the Company has the ability to appoint two of the three members of the board of directors of the general partner of the partnership. As a result, we have consolidated SH Acquisition as a subsidiary of Tilray beginning on August 17, 2021. Additional information about the MM Transaction is included in Note 7, Long-term investments.

Long-term investments

Debt securities are classified as available-for-sale and are recorded at fair value and are subject to impairment testing. Other than impairment losses, unrealized gains and losses during the period, net of the related tax effect, are excluded from income and reflected in other comprehensive income (loss), and the cumulative effect is reported as a separate component of shareholders’ equity until realized. Upon sale, realized gain and losses are reported in net income. Debt securities are impaired when a decline in fair value is determined to be other-than-temporary. If the cost of an investment exceeds its fair value, the Company evaluates, among other factors, general market conditions, credit quality of debt instrument issuers, and the duration and extent to which the fair value is less than cost. Once a decline in fair value is determined to be other-than-temporary, an impairment charge is recorded in the statements of net loss and a new cost basis for the investment is established. The Company also evaluates whether there is a plan to sell the security or it is more likely than not that the Company will be required to sell the security before recovery. If neither of the conditions exist, then only the portion of the impairment loss attributable to credit loss is recorded in the statements of net loss and the remaining amount is recorded in other comprehensive income (loss).

Investments in equity securities of entities over which the Company does not have a controlling financial interest or significant influence are accounted for at fair value. Equity investments without readily determinable fair values are measured at cost with adjustments for observable changes in price or impairments (referred to as the “measurement alternative”). In applying the measurement alternative, the Company performs a qualitative assessment on a quarterly basis and recognizes an impairment if there are sufficient indicators that the fair value of the equity investments are less than carrying values. Changes in value are recorded in the statement of net loss and comprehensive loss, within the line, “Non-operating income (expense)”.

Investments in entities over which the Company does not have a controlling financial interest but has significant influence, are accounted for using the equity method, with the Company’s share of earnings or losses reported in earnings or losses from equity method investments on the statements of net loss and comprehensive loss. Equity method investments are recorded at cost, plus the Company’s share of undistributed earnings or losses, and impairment, if any, within “Interest in Equity Investees” on the balance sheets. The Company assesses investments in equity method investments when events or circumstances indicate that the carrying amount of the investment may be impaired. If it is determined that the current fair value of an equity method investment is less than the carrying value of the investment, the Company will assess if the shortfall is other than temporary (OTTI). Evidence of a loss in value might include, but would not necessarily be limited to, absence of an ability to recover the carrying amount of the investment or inability of the equity investee to sustain an earnings capacity that would justify the carrying amount of the investment. Once a determination is made that an OTTI exists, the investment is written down to its fair value in accordance with ASC 820 at the reporting date, which establishes a new cost basis.

New accounting pronouncements not yet adopted

In August 2020, the FASB issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”), which amends and simplifies existing guidance in an effort to reduce the complexity of

accounting for convertible instruments and to provide financial statement users with more meaningful information. ASU 2020-06 is effective for the Company beginning June 1, 2022. This update may be applied retrospectively or on a modified retrospective basis with the cumulative effect recognized as an adjustment to the opening balance of retained earnings on the date of adoption. The Company is currently evaluating the effect of adopting this ASU.

In May 2021, the FASB issued ASU 2021-04, Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40) (“ASU 2021-04”), which amends existing guidance for earnings per share (EPS) in accordance with Topic 260. ASU 2021-04 is effective for the Company beginning June 1, 2022. This update should be applied prospectively on or after the effective date of the amendments. The Company is currently evaluating the effect of adopting this ASU.

New accounting pronouncements recently adopted

In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740) – Simplifying the Accounting for Income Taxes (“ASU 2019-12”), which is intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. The standard is effective for annual reporting periods beginning after December 15, 2021 and including interim periods within those fiscal years. The Company adopted the ASU beginning June 1, 2021 and the adoption of ASU 2019-12 did not have a material impact on our consolidated financial statements.

In January 2020, the FASB issued ASU 2020-01, Investments – Equity Securities (Topic 321), Investments - Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815) (“ASU 2020-01”), which is intended to clarify the interaction of the accounting for equity securities under Topic 321 and investments accounted for under the equity method of accounting in Topic 323 and the accounting for certain forward contracts and purchased options accounted for under Topic 815. The Company adopted the ASU beginning June 1, 2021 and the adoption of ASU 2020-01 did not have a material impact on our consolidated financial statements.

Inventory

3 Months Ended

Aug. 31, 2021

Inventory Disclosure [Abstract]

Inventory

Note 3. Inventory

Inventory is comprised of:

	August 31, 2021		May 31, 2021
Plants	$	19,605	$	23,083
Dried cannabis		113,180		118,269
Cannabis trim		3,448		2,931
Cannabis derivatives		38,613		24,158
Cannabis vapes		3,543		3,791
Packaging and other inventory items		25,595		31,462
Wellness inventory		14,042		15,171
Beverage alcohol inventory		4,796		5,402
Distribution inventory		28,685		32,162
Total	$	251,507	$	256,429

Capital assets

3 Months Ended

Aug. 31, 2021

Property Plant And Equipment [Abstract]

Capital assets

Note 4. Capital assets

Capital asset consisted of the following:

	August 31, 2021			May 31, 2021
Land	$	31,467		$	28,549
Production facility		413,711			346,510
Equipment		231,290			215,408
Leasehold improvement		7,477			17,059
ROU-assets under finance lease		35,290			34,726
Construction in progress		19,174			85,322
	$	738,408		$	727,574
Less: accumulated amortization		(117,070	)		(76,876	)
Total	$	621,339		$	650,698

Intangible Assets

3 Months Ended

Aug. 31, 2021

Intangible Assets Net Excluding Goodwill [Abstract]

Intangible Assets

Note 5. Intangible Assets

Intangible assets are comprised of the following items:

										Intellectual
	Customer									property,
	relationships			Licenses,			Non-			trademarks,			Total
	& distribution			permits &			compete			know how			intangible
	channel			applications			agreements			& brands			assets
Cost
At May 31, 2021	$	239,810		$	414,930		$	12,453		$	990,917		$	1,658,110
Additions		—			182			—			856			1,038
Effect of foreign exchange		(9,300	)		(17,346	)		(659	)		(51,738	)		(79,043	)
At August 31, 2021	$	230,510			397,766			11,794			940,035		$	1,580,105
Accumulated amortization
At May 31, 2021	$	18,302			1,167			4,299			28,424		$	52,192
Amortization		9,466		116			833				14,684			25,099
At August 31, 2021	$	27,768		$	1,283		$	5,132		$	43,108		$	77,291
Net book value at May 31, 2021	$	221,508		$	413,763		$	8,154		$	962,493		$	1,605,918
Net book value at August 31, 2021	$	202,742		$	396,483		$	6,662		$	896,927		$	1,502,814

As of August 31, 2021, included in Licenses, permits & applications is $408,000 of indefinite-lived intangible assets (May 31, 2021 - $412,000).

Expected future amortization expense for intangible assets as of August 31, 2021 are as follows:

	Amortization
2022 (remaining nine months)	$	48,820
2023		67,556
2024		64,084
2025		61,297
2026		61,297
Thereafter		791,760
Total	$	1,094,814

Goodwill

3 Months Ended

Aug. 31, 2021

Goodwill Disclosure [Abstract]

Goodwill

Note 6. Goodwill

The following table shows the change in the carrying amount of goodwill:

		August 31,		May 31,
	Segment	2021		2021
Broken Coast Cannabis Ltd.	Cannabis business	$	105,963	$	105,963
Nuuvera Corp.	Cannabis business		273,606		273,606
LATAM Holdings Inc.	Cannabis business		63,239		63,239
CC Pharma GmbH	Distribution business		4,458		4,458
SweetWater	Beverage alcohol business		100,202		100,202
Tilray	Cannabis business		2,144,143		2,144,143
Tilray	Wellness business		77,470		77,470
Effect of foreign exchange			40,050		63,713
Total		$	2,809,131	$	2,832,794

Long-term investments

3 Months Ended

Aug. 31, 2021

Investments All Other Investments [Abstract]

Long-term investments

Note 7. Long term investments

Long term investments are comprised of:

	August 31, 2021		May 31, 2021
Debt securities classified under available-for-sale method	$	170,799	$	—
Equity investments measured at fair value		10,108		12,185
Equity investments under measurement alternative		5,500		5,500
Total investments in debt and equity securities	$	186,407	$	17,685

The Company’s debt securities under available-for-sale method include the MM Notes, described in Note 2. Basis of presentation and summary of significant accounting policies, originally issued by unrelated third parties, MedMen with an interest rate of LIBOR plus 6%, with a LIBOR floor of 2.5% and with contractual maturity in 2028, which are held by its majority-owned subsidiary Superhero Acquisition. SH Acquisition has the ability, at its own discretion, to transfer its partnership interest, and/or the pro rata portion of the MM Notes and the corresponding portion of accrued and unpaid interest, and/or cause the redemption of the partnership interest and/or the pro rata portion of the MM Notes held by the minority interest at any time.

The Company’s equity investments at fair value consist of publicly traded shares and warrants held by the Company including certain warrants acquired conjunctively with the MM Notes and exercisable for equity securities of MedMen’s Class B subordinate voting shares. The Company’s equity investment under measurement alternative includes equity investments without readily determinable fair values.

The following table summarizes the activity related to equity investments for the three months ended August 31, 2021.

			Changes in fair
	May 31, 2021		value recorded in			Sales / purchases /		August 31, 2021
	Carrying value		net loss			other		Carrying value
Debt securities classified under available-for-sale method	$	—		—			170,799	$	170,799
Equity investments with readily determinable value	$	12,185		(2,077	)		—	$	10,108
Equity investments without readily determinable value	$	5,500		—			—	$	5,500

Accounts payable and accrued liabilities

3 Months Ended

Aug. 31, 2021

Payables And Accruals [Abstract]

Accounts payable and accrued liabilities

Note 8. Accounts payable and accrued liabilities

Accounts payable and accrued liabilities are comprised of:

	August 31,		May 31,
	2021		2021
Trade payables	$	61,990	$	57,706
Accrued liabilities		85,977		112,594
Accrued payroll and employment related taxes		23,486		19,390
Income taxes payable		14,023		14,764
Accrued interest		3,440		148
Other accruals		1,297		8,211
Total	$	190,213	$	212,813

Bank indebtedness

3 Months Ended

Aug. 31, 2021

Bank Indebtedness [Abstract]

Bank indebtedness

Note 9. Bank indebtedness

The Company secured an operating line of credit in the amount of C$1,000 which bears interest at the lender’s prime rate plus 75 basis points. As of August 31, 2021, the Company has not drawn on the line of credit. The operating line of credit is secured by a first charge on the property at 265 Talbot St. West, Leamington, Ontario and a first ranking position on a general security agreement.

The Company’s subsidiary, CC Pharma, has two operating lines of credit for €5,000 and €3,500 each, which bear interest at Euro Over Night Index Average plus 1.79% and Euro Interbank Offered Rate plus 3.682% respectively. As of August 31, 2021, a total of €7,000 ($8,413) was drawn down from the available credit of €8,500. The operating lines of credit are secured by a first charge on the inventory held by CC Pharma.

The Company’s subsidiary, Four Twenty Corporation (“420”), has a revolving credit facility of $20,000 which bears interest at EURIBOR plus an applicable margin. As of August 31, 2021, the Company has not drawn any amount on the revolving line of credit. The revolving credit facility is secured by all of 420 and SweetWater’s assets and includes a corporate guarantee by a subsidiary of the Company.

Long-term debt

3 Months Ended

Aug. 31, 2021

Long Term Debt [Abstract]

Long-term debt

Note 10. Long-term debt

The following table sets forth the net carrying amount of long-term debt instruments:

	August 31,			May 31,
	2021			2021
Credit facility - C$80,000 - Canadian prime interest rate plus an applicable margin, 3-year term, with a 10-year amortization, repayable in blended monthly payments, due in November 2022	$	58,730		$	62,964
Term loan - C$25,000 - Canadian 5-year bond interest rate plus 2.73% with a minimum 4.50%, 5-year term, with a 15-year amortization, repayable in blended monthly payments, due in July 2023		13,454			14,335
Term loan - C$25,000 - 3.95%, compounded monthly, 5-year term with a 15-year amortization, repayable in equal monthly instalments of $188 including interest, due in April 2022		16,011			17,117
Term loan - C$1,250 - 3.85%, 5-year term, with a 10-year amortization, repayable in equal monthly instalments of $13 including interest, due in August 2026		538			587
Mortgage payable - C$3,750 - 3.85%, 5-year term, with a 20-year amortization, repayable in equal monthly instalments of $23 including interest, due in August 2026		2,425			2,562
Vendor take-back mortgage - C$2,850 - 6.75%, 5-year term, repayable in equal monthly instalments of $56 including interest, due in June 2021		-			92
Term loan ‐ €5,000 ‐ Euro Interbank Offered Rate + 1.79%, 5‐year term, repayable in quarterly instalments of €250 plus interest, due in December 2023		3,239			3,356
Term loan ‐ €5,000 ‐ Euro Interbank Offered Rate + 2.68%, 5‐year term, repayable in quarterly instalments of €250 plus interest, due in December 2023		3,239			3,356
Term loan ‐ €1,500 ‐ Euro Interbank Offered Rate + 2.00%, 5‐year term, repayable in quarterly instalments of €98 including interest, due in April 2025		1,767			1,831
Term loan ‐ €1,500 ‐ Euro Interbank Offered Rate + 2.00%, 5‐year term, repayable in quarterly instalments of €98 including interest, due in June 2025		1,767			1,831
Term loan - $100,000 - EUROBIR rate plus an applicable margin, 3-year term, repayable in quarterly instalments beginning March 31, 2021 of $7,500 in its first twelve months and $10,000 in each of the next two years, due in March 2024		96,250			98,138
Carrying amount of long-term debt		197,420			206,169
Unamortized financing fees		(1,672	)		(2,061	)
Net carrying amount		195,748			204,108
Less principal portion included in current liabilities		(30,837	)		(36,622	)
Total noncurrent portion of long-term debt	$	164,911		$	167,486

As of August 31, 2021, the Company was in compliance with all the long-term debt covenants.

Convertible debentures

3 Months Ended

Aug. 31, 2021

Debt Instruments [Abstract]

Convertible debentures

Note 11. Convertible debentures

The following table sets forth the net carrying amount of the convertible debentures:

	August 31,		May 31,
	2021		2021
5.25% Convertible Notes ("APHA 24")	$	342,499	$	399,444
5.00% Convertible Notes ("TLRY 23")		269,147		268,180
Total	$	611,646	$	667,624

APHA 24

	August 31,			May 31,
	2021			2021
5.25% Contractual debenture	$	350,000		$	350,000
Debt settlement		(90,760	)		(90,760	)
Fair value adjustment		83,259			140,204
Net carrying amount of APHA 24	$	342,499		$	399,444

The Company estimated the fair value of the APHA 24 convertible debenture at August 31, 2021 at $1,321 per convertible debenture using the Black-Scholes model (Level 3) with the following weighted-average assumptions:

Risk-free interest rate		0.84	%
Expected volatility		70	%
Expected term	2.75 years
Expected dividend yield		0.0	%

Expected volatility is based on the historical volatility of the Company's common stock since its initial public offering in 2018.

TLRY 23

	August 31,			May 31,
	2021			2021
5.00% Contractual debenture	$	277,856		$	277,856
Unamortized discount		(8,709	)		(9,676	)
Net carrying amount of TLRY 23	$	269,147		$	268,180

Warrant liability

3 Months Ended

Aug. 31, 2021

Warrants And Rights Note Disclosure [Abstract]

Warrant Liability

Note 12. Warrant liability

Warrants outstanding at August 31, 2021:

			Balance						Balance
	Classification	Exercise Price	May 31, 2021		Issued		Exercised		August 31, 2021
Warrant – September 26, 2021	Equity	3.14		166,000		—		—		166,000
Warrant – January 30, 2022	Equity	9.26		5,828,651		—		—		5,828,651
Warrant – March 17, 2025	Liability	5.95		6,209,000		—		—		6,209,000
				12,203,651		—		—		12,203,651

	August 31, 2021				August 31, 2020
			Weighted				Weighted
	Number of		average		Number of		average
	warrants		price		warrants		price
Outstanding, opening		12,203,651	$	7.41		5,994,651	$	8.91
Exercised during the period		—		—		—		—
Issued during the period		—		—		—		—
Cancelled during the period		—		—		—		—
Expired during the period		—		—		—		—
Outstanding, ending		12,203,651	$	7.41		5,994,651	$	8.91

The Company estimated the fair value of the Warrant liability at August 31, 2021 at $9.74 per warrant using the Black-Scholes pricing model (Level 3) with the following weighted-average assumptions:

Risk-free interest rate		0.84	%
Expected volatility		70	%
Expected term	4.05 years
Expected dividend yield		0.0	%
Strike price	$	5.95
Fair value of common stock	$	13.69

Stock-based compensation

3 Months Ended

Aug. 31, 2021

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Stock-based compensation

Note 13. Stock-based compensation

For the three months ended August 31, 2021, the total stock-based compensation was $9,417 (2020 - $2,850). The Company operates the following stock-based compensation plans:

Tilray 2018 Equity Incentive Plan and Original Plan

The 2018 Equity Incentive Plan (EIP) authorizes the award of stock options, restricted stock units (“RSUs”) and stock appreciation rights (“SARs”) to employees, including officers, non-employee directors and consultants and the employees and consultants of our affiliates. Certain employees and other service providers of the Company participate in the equity-based compensation plan of Privateer Holdings, Inc (the “Original Plan”).

No stock options were granted under the EIP during the three months ended August 31, 2021, and three months ended August, 31, 2020.

Stock-based activity under the EIP and Original Plan for the year ended August 31, 2021 is as follows:

EIP Time-based stock option activity
						Weighted-
				Weighted-		average
				average		remaining
	Stock			exercise		contractual		Aggregate
	Options			price		term (years)		intrinsic value
Balance, May 31, 2021		3,180,226		$	14.19	1.3		$	25,171
Granted		—			—		—		—
Exercised		(67,750	)		7.76		—		—
Forfeited		(112,306	)		21.40		—		—
Cancelled		(2,498	)		65.20		—		—
Balance, August 31, 2021		2,997,672		$	14.02	6.5		$	15,843

Original plan time-based stock option activity
						Weighted-
				Weighted-		average
				average		remaining
	Stock			exercise		contractual		Aggregate
	Options			price		term (years)		intrinsic value
Balance, May 31, 2021		917,545		$	3.97	1.7		$	11,886
Exercised		(411,742	)		3.41		—		—
Forfeited		(4,250	)		4.79		—		—
Cancelled		(16,093	)		26.30		—		—
Balance, August 31, 2021		485,460		$	3.69		2.7	$	4,954

EIP Time-based RSU activity
				Weighted- average		Weighted- average
				grant-date		remaining
	Time-based			fair value		contractual		Aggregate
	RSUs			per share		term (years)		intrinsic value
Balance, May 31, 2021		1,205,243		$	15.16		—	$	20,091
Granted		981,229			14.39		—		—
Vested		(126,393	)		19.52		—		—
Forfeited		(121,295	)		16.39		—		—
Cancelled		—			—		—		—
Balance, August 31, 2021		1,938,784		$	14.41		—	$	28,709

EIP Performance-based RSU activity
			Weighted- average		Weighted- average
			grant-date		remaining
	Performance-based		fair value		contractual		Aggregate
	RSUs		per share		term (years)		intrinsic value
Balance, May 31, 2021		—	$	—		—	$	—
Granted		1,345,158		13.13		—		17,668
Vested		—		—		—		—
Forfeited		—		—		—		—
Cancelled		—		—		—		—
Balance, August 31, 2021		1,345,158	$	13.13		2.9	$	17,668

For the three months ended August 31, 2021, the Company granted 1,345,158 performance-based RSUs, with none vesting in the period (2020 – none).

Predecessor Plan – Aphria

Prior to the reverse acquisition disclosed in our annual report, Aphria had established the Aphria Omnibus Incentive Plan (the “Predecessor Plan”). Following stockholder approval of the EIP, no new awards have been granted under the Predecessor Plan. In connection with the reverse acquisition Aphria stock options, Aphria RSUs and DSUs issued under the Predecessor Plan were exchanged for options, RSUs under the EIP.

Stock option, RSU and DSU activity for the Company under the Predecessor Plan is as follows:

Predecessor plan time-based stock option activity

	August 31, 2021
						Weighted		Weighted
				Weighted		average		average
				average		grant		remaining		Aggregate
	Number of			exercise		date fair		contractual		Intrinsic
	options			price		value		term (years)		Amount
Balance May 31, 2021		2,499,185		$	12.48	$	6.51		2.4		(10,472	)
Granted		—			—		—		—		—
Exercised		(56,301	)		9.34		4.50		—		—
Forfeited		(638	)		8.95		4.15		—		—
Expired		(405,455	)		19.94		9.29		—		—
Balance, August 31, 2021		2,036,790		$	11.08	$	6.02		2.67	$	5,321
Vested and exercisable, August 31, 2021		1,821,178		$	11.17	$	6.10		2.65	$	4,588

During the three months ended August 31, 2021, the Company did not grant any further stock options out of the Predecessor plan. The total intrinsic values of the stock options exercised during the three months ended August 31, 2021 was $430 (2020 - $238). The total fair value of time-based stock options vested during the three months ended August 31, 2021 was $1,797 (2020 - $1,723).

Predecessor plan time-based and Performance-based RSU activity

	August 31, 2021
				Weighted				Weighted
				average				average
				grant -				grant -
				date fair		Performance-		date fair
	Time- based			value per		based		value per
	RSUs			share		RSUs		share
Balance, May 31, 2021		2,794,972		$	6.88		—		—
Granted		—			—		—		—
Exercised		(1,574,381	)		6.56		—		—
Forfeited		(46,171	)		15.09		—		—
Balance, August 31, 2021		1,174,419		$	6.98		—		—

As of August 31, 2021, the total remaining unrecognized compensation expenses related to non-vested time-based RSUs amounted to $789 (2021 - $15,111), which will be amortized over the weighted-average remaining requisite service period of approximately 1.04 years (2020 – 1.85 years). The total fair value of time-based RSUs vested during the three months ended August 31, 2021 was $12,063 (2020 - $862). During the period, the Company accelerated the vesting of 679,000 RSUs to fully vested.

Accumulated other comprehensive income (loss)

3 Months Ended

Aug. 31, 2021

Equity [Abstract]

Accumulated other comprehensive income (loss)

Note 14. Accumulated other comprehensive income (loss)

Accumulated other comprehensive loss includes the following components:

	Foreign currency translation gain (loss)			Unrealized loss on convertible notes receivables			Total
Balance May 31, 2021	$	156,417		$	(3,749	)	$	152,668
Other comprehensive loss		(100,772	)		(649	)		(101,421	)
Balance August 31, 2021	$	55,645		$	(4,398	)	$	51,247

Non-controlling interests

3 Months Ended

Aug. 31, 2021

Text Block [Abstract]

Non-controlling interests

Note 15. Non-controlling interests

The following tables summarize the information relating to the Company’s subsidiaries, Superhero LP, CC Pharma Nordic ApS, Aphria Diamond, and ColCanna S.A.S. before intercompany eliminations.

Non-controlling interests as of August 31, 2021:

	Superhero			CC Pharma			Aphria			ColCanna			August 31,
	LP			Nordic ApS			Diamond			S.A.S.			2021
Current assets	$	52,995		$	951		$	26,058		$	527		$	80,531
Non-current assets		170,799			132			156,839			141,387			469,157
Current liabilities		(170,799	)		(1,033	)		(16,047	)		(66	)		(187,945	)
Non-current liabilities		—			(392	)		(80,543	)		(23,581	)		(104,516	)
Net assets	$	52,995		$	(343	)	$	86,307		$	118,267		$	257,227

Non-controlling interests as of May 31, 2021:

	CC Pharma			Aphria			ColCanna			May 31,
	Nordic ApS			Diamond			S.A.S.			2021
Current assets	$	919		$	19,531		$	315		$	20,765
Non-current assets		103			153,696			146,587			300,386
Current liabilities		(956	)		(28,511	)		(62	)		(29,529	)
Non-current liabilities		(406	)		(69,332	)		(6,606	)		(76,344	)
Net assets	$	(340	)	$	75,384		$	140,234		$	215,278

Non-controlling interests for the three months ended August 31, 2021:

	Superhero		CC Pharma			Aphria		ColCanna			August 31,
	LP		Nordic ApS			Diamond		S.A.S.			2021
Revenue	$	—	$	—		$	20,325	$	—		$	20,325
Total expenses		—		4			13,274		2			13,280
Net (loss) income		—		(4	)		7,051		(2	)		7,045
Other comprehensive (loss) income		—		—			—		—			—
Net comprehensive income	$	—	$	(4	)	$	7,051	$	(2	)	$	7,045

Non-controlling interests for the three months ended August 31, 2020:

	CC Pharma		Aphria		ColCanna			August 31,
	Nordic ApS		Diamond		S.A.S.			2020
Revenue	$	—	$	30,035	$	—		$	30,035
Total expenses (recovery)		—		17,675		(239	)		17,436
Net (loss) income		—		12,360		239			12,599
Other comprehensive (loss) income		—		—		—			—
Net comprehensive income	$	—	$	12,360	$	239		$	12,599

Commitments and contingencies

3 Months Ended

Aug. 31, 2021

Commitments And Contingencies Disclosure [Abstract]

Commitments and contingencies

Note 16. Commitments and contingencies

Purchase and other commitments

The Company has payments on long-term debt (refer to Note 10 Long-term debt), convertible notes (refer to Note 11 Convertible Debentures), ABG finance liability material purchase commitments and construction commitments as follows:

	Total		2022 (remaining nine months)		2023		2024		2025		2026		Thereafter
Long-term debt repayment	$	198,253	$	32,981	$	78,820	$	80,838	$	2,157	$	2,516	$	941
Convertible notes, principal and interest		571,989		13,893		13,893		284,803		259,400		—		—
ABG finance liability		6,000		1,500		1,500		1,500		1,500		—		—
Material purchase obligations		29,523		24,222		4,185		937		179		—		—
Construction commitments		2,012		2,012		—		—		—		—		—
Total	$	807,776	$	74,608	$	98,398	$	368,077	$	263,236	$	2,516	$	941

Escrow payable was settled on September 17, 2021, when the Company issued 9,817,061 shares of its common stock, while non-controlling interest holders contributed cash.

The following table presents the future undiscounted payment associated with lease liabilities as of August 31, 2021:

	Operating			Finance
	leases			leases
2022 (remaining nine months)		3,832			1,672
2023		4,437			7,088
2024		3,840			2,061
2025		3,321			2,122
2026		3,472			2,186
Thereafter		8,522			39,586
Total minimum lease payments	$	27,423		$	54,715
Imputed interest		(5,778	)		(19,167	)
Obligations recognized	$	21,645		$	35,548

Net revenue

3 Months Ended

Aug. 31, 2021

Revenues [Abstract]

Net revenue

Note 17. Net revenue

The Company reports four segments: cannabis, distribution, beverage alcohol and wellness, in accordance with ASC 280 Segment Reporting. The Company generates revenues from these segments through contracts with customers, each with a single performance obligation, being the sale of products. The Company determines that revenue information disclosed in business segment information in (Note 22 Segment reporting) disaggregates revenue into categories that depict how the nature, amount, timing and uncertainty of revenue and cash flows are affected by economic factors.

Net revenue is comprised of:

	For the three months ended August 31.
	2021			2020
Cannabis revenue	$	89,933		$	67,120
Cannabis excise taxes		(19,484	)		(15,918	)
Net cannabis revenue		70,449			51,202
Beverage alcohol revenue		16,483			—
Beverage alcohol excise taxes		(1,022	)		—
Net beverage alcohol revenue		15,461			—
Distribution revenue		67,186			66,288
Wellness revenue		14,927			—
Total	$	168,023		$	117,490

- Definition

The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-URI http://asc.fasb.org/topic&trid=49130388

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130550-203045

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130558-203045

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045

+ Details

Cost of goods sold

3 Months Ended

Aug. 31, 2021

Cost Of Goods And Services Sold [Abstract]

Cost of goods sold

Note 18. Cost of goods sold

Cost of goods sold is comprised of:

	For the three months ended August 31,
	2021		2020
Cannabis costs	$	40,190	$	25,775
Beverage alcohol costs		6,662		—
Distribution costs		59,290		56,770
Wellness costs		10,925		—
Total	$	117,068	$	82,545

General and administrative expenses

3 Months Ended

Aug. 31, 2021

General And Administrative Expense [Abstract]

General and administrative expenses

Note 19. General and administrative expenses

General and administrative expenses are comprised of:

	For the three months ended August 31,
	2021		2020
Executive compensation	$	3,090	$	2,250
Office and general		12,769		4,421
Salaries and wages		15,311		9,343
Stock-based compensation		9,417		2,850
Insurance		4,631		3,206
Professional fees		2,713		2,935
Travel and accommodation		790		727
Rent		766		240
Total	$	49,487	$	25,972

Non-operating income (expense)

3 Months Ended

Aug. 31, 2021

Nonoperating Income Expense [Abstract]

Non-operating income (expense)

Note 20. Non-operating income (expense)

Non-operating income (expense) is comprised of:

	For the three months ended August 31,
	2021			2020
Change in fair value of convertible debenture	$	39,370		$	340
Change in fair value of warrant liability		17,535			—
Foreign exchange loss		(5,724	)		(16,331	)
Loss on long-term investments		(1,675	)		(1,120	)
Gain from equity investees		1,356			—
Other non-operating (losses) gains, net		(2,002	)		3,752
Total	$	48,860		$	(13,359	)

Financial risk management and financial instruments

3 Months Ended

Aug. 31, 2021

Financial Risk Management And Financial Instruments [Abstract]

Financial risk management and financial instruments

Note 21.

Financial risk management and financial instruments

Financial instruments

The Company has classified its financial instruments as described in Note 3 Significant accounting policies in our Annual Report.

The carrying values of accounts receivable, bank indebtedness and accounts payable and accrued liabilities approximate their fair values due to their short periods to maturity.

The Company’s long-term debt of $18,974 (2021 - $20,358) is subject to fixed interest rates. The Company’s long-term debt is valued based on discounting the future cash outflows associated with the long-term debt. The discount rate is based on the incremental premium above market rates for Government of Canada securities of similar duration. In each period thereafter, the incremental premium is held constant while the Government of Canada security is based on the then current market value to derive the discount rate.

Fair value hierarchy

The Company complies with ASC 820, Fair Value Measurements, for its financial assets and liabilities that are re-measured and reported at fair value at each reporting period, and non-financial assets and liabilities that are re-measured and reported at fair value at least annually. In general, fair values determined by Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities. Fair values determined by Level 2 inputs utilize data points that are observable such as quoted prices, interest rates and yield curves. Fair values determined by Level 3 inputs are unobservable data points for the asset or liability, and includes situations where there is little, if any, market activity for the asset or liability.

The following tables present information about the Company’s assets and liabilities that are measured at fair value on a recurring basis as of August 31, 2021 and May 31, 2021 and indicates the fair value hierarchy of the valuation techniques the Company utilized to determine such fair value:

							August 31,
	Level 1		Level 2		Level 3		2021
Financial assets
Cash and cash equivalents	$	376,297	$	—	$	—	$	376,297
Convertible notes receivable		—		2,370		—		2,370
Long-term investments		7,174		173,733		—		180,907
Financial liabilities
Warrant liability		—		—		60,476		60,476
Contingent consideration		—		—		61,494		61,494
APHA 24 Convertible debenture		—		—		342,499		342,499
Total recurring fair value measurements	$	383,471	$	176,103	$	464,468	$	1,024,042

							May 31,
	Level 1		Level 2		Level 3		2021
Financial assets
Cash and cash equivalents	$	488,466	—		—		$	488,466
Convertible notes receivable	—			2,485	—			2,485
Long-term investments		9,251		2,934	—			12,185
Financial liabilities
Warrant liability	—		—			78,168		78,168
Contingent consideration	—		—			60,657		60,657
APHA 24 Convertible debenture	—		—			399,444		399,444
Total recurring fair value measurements	$	497,717	$	5,419	$	538,269	$	1,041,405

The Company’s financial assets and liabilities required to be measured on a recurring basis are its equity investments measured at fair value, debt securities classified as available-for-sale, acquisition-related contingent consideration, and warrant liability.

Convertible notes receivable and long-term investments recorded at fair value: The estimated fair value is determined using quoted market prices, broker or dealer quotations or discounted cash flows and is classified as Level 2.

Warrant liability: The warrants associated with the warrant liability are classified as Level 3 derivatives. Consequently, the estimated fair value of the warrant liability is determined using the Black-Scholes pricing model. Until the warrants are exercised, expire, or other facts and circumstances lead the warrant liability to be reclassified to stockholders’ equity, the warrant liability (which relates to warrants to purchase shares of common stock) is marked-to-market each reporting period with the change in fair value recorded in change in fair value of warrant liability. Any significant adjustments to the unobservable inputs disclosed in the table below would have a direct impact on the fair value of the warrant liability.

APHA 24: This instrument is held at fair value. The estimated fair value is determined using the Black-Scholes option pricing model and is classified as Level 3.

Contingent consideration: The contingent consideration from the acquisition of SweetWater is determined by discounting future expected cash outflows at a discount rate of 5%. The inputs into the future expected cash outflows are classified as Level 3.

The balances of assets and liabilities categorized within Level 3 of the fair value hierarchy measured at fair value on a recurring basis are reconciled, as follows:

	APHA 24
	Convertible			Warrant			Contingent
	Debt			Liability			Consideration			Total
Balance, May 31, 2021		(399,444	)		(78,168	)		(60,657	)		(538,269	)
Additions		—			—			—			—
Disposals		—			—			—			—
Unrealized gain (loss) on fair value		56,945			17,692			(837	)		73,800
Balance, August 31, 2021		(342,499	)		(60,476	)		(61,494	)		(464,469	)

The unrealized gain (loss) on fair value for the Convertible Debenture and the warrant liability is recognized in non-operating income (loss) using the following inputs:

Financial asset / financial liability	Valuation technique	Significant unobservable input	Inputs
APHA Convertible debentures	Black-Scholes	Volatility, expected life	70% 3 years
Warrant liability	Black-Scholes	Volatility, expected life	70% 4 years
Contingent consideration	Discounted cash flows	Discount rate, achievement	5% 100%

Items measured at fair value on a non-recurring basis

The Company's prepaids and other current assets, long lived assets, including property and equipment, goodwill and intangible assets are measured at fair value when there is an indicator of impairment and are recorded at fair value only when an impairment charge is recognized.

Financial risk management

The Company has exposure to the following risks from its use of financial instruments: credit; liquidity; currency rate; interest rate price; equity price risk; and capital management risk.

(a)

Credit risk

Credit risk is the risk of financial loss to the Company if a customer or counterparty to a financial instrument fails to meet its contractual obligations. The maximum credit exposure at August 31, 2021, is the carrying amount of cash and cash equivalents, accounts receivable, prepaids and other current assets, and convertible notes receivable. All cash and cash equivalents are placed with major financial institutions in Canada, Australia, Portugal, Germany, Colombia, Argentina and the United States. To date, the Company has not experienced any losses on its cash deposits. Accounts receivable are unsecured, and the Company does not require collateral from its customers.

The Company evaluates the collectability of its accounts receivable and maintains an allowance for credit losses at an amount sufficient to absorb losses inherent in the existing accounts receivable portfolio as of the reporting dates based on the estimate of expected net credit losses.

Due to the uncertainties associated with COVID-19, the Company may be unable to accurately predict the creditworthiness of its counterparties and their ability to meet their obligations. This may result in unforeseen additional credit losses.

(b)

Liquidity risk

As of August 31, 2021, the Company’s financial liabilities consist of bank indebtedness and accounts payable and accrued liabilities, which have contractual maturity dates within one-year, long-term debt, and convertible debentures which have contractual maturities over the next five years.

The Company maintains a debt service charge covenant on certain loans secured by its Aphria One facilities that is measured at year-end only. The Company maintains debt service charge and leverage covenants on certain loans secured by its Aphria Diamond facilities and 420 that are measured quarterly. The Company believes that it has sufficient operating room with respect to its financial covenants for the next fiscal year and does not anticipate being in breach of any of its financial covenants.

The Company manages its liquidity risk by reviewing its capital requirements on an ongoing basis. Based on the Company’s working capital position at August 31, 2021, management regards liquidity risk to be low.

(c)

Currency rate risk

As of August 31, 2021, a portion of the Company’s financial assets and liabilities held in Canadian dollars and Euros consist of cash and cash equivalents, convertible notes receivable, and long-term investments. The Company’s objective in managing its foreign currency risk is to minimize its net exposure to foreign currency cash flows by transacting, to the greatest extent possible, with third parties in the functional currency. The Company is exposed to currency rate risk in other comprehensive income, relating to foreign subsidiaries which operate in a foreign currency. The Company does not currently use foreign exchange contracts to hedge its exposure of its foreign currency cash flows as management has determined that this risk is not significant at this point in time.

(d)

Interest rate price risk

The Company’s exposure to changes in interest rates relates primarily to the Company’s outstanding debt. The Company manages interest rate risk by restricting the type of investments and varying the terms of maturity and issuers of marketable securities. Varying the terms to maturity reduces the sensitivity of the portfolio to the impact of interest rate fluctuations.

(e)

Equity price risks

As of August 31, 2021, the Company held long-term equity investments at fair value and equity investments under the measurement alternative. These investment in equities were acquired as part of our strategic transactions. Accordingly, the changes in fair values of investment in equities measured at fair value or under the measurement alternative are recognized through gain (loss) on long-term investment in the statements of net loss and comprehensive loss. Based on the fair value of investment in equities held as of August 31, 2021, a hypothetical decrease of 10% in the prices for these companies would reduce the fair values of the investments and result in unrealized loss recorded in gain (loss) on long-term investment by $18,641.

Similarly, based on the fair value of our warrant liability as of August 31, 2021, a hypothetical increase of 10% in the price for our common stock would increase the change in fair value of warrant liability and result in unrealized gain recorded in non-operating income by $6,047.

(f)

Capital management

The Company’s objectives when managing its capital are to safeguard its ability to continue as a going concern, to meet its capital expenditures for its continued operations, and to maintain a flexible capital structure which optimizes the cost of capital within a framework of acceptable risk. The Company manages its capital structure and adjusts it in light of changes in economic conditions and the risk characteristics of the underlying assets. To maintain or adjust its capital structure, the Company may issue new shares, issue new debt, or acquire or dispose of assets. The Company is not subject to externally imposed capital requirements.

Management reviews its capital management approach on an ongoing basis and believes that this approach, given the relative size of the Company, is reasonable. There have been no changes to the Company’s capital management approach in the year. The Company considers its cash and cash equivalents and marketable securities as capital.

Segment reporting

3 Months Ended

Aug. 31, 2021

Segment Reporting [Abstract]

Segment reporting

Note 22.

Segment reporting

Information reported to the Chief Operating Decision Maker (“CODM”) for the purpose of resource allocation and assessment of segment performance focuses on the nature of the operations. The Company operates in four segments. 1) cannabis operations, which encompasses the production, distribution and sale of both medical and adult-use cannabis, 2) beverage alcohol operations, which encompasses cultivation, distribution and sale of beverage alcohol products, 3) distribution operations, which encompasses the purchase and resale of pharmaceuticals products to customers, and 4) wellness products, which encompasses hemp foods and cannabidiol (“CBD”) products. Operating segments have not been aggregated and no asset information is provided for the segments because the Company’s CODM does not receive asset information by segment on a regular basis. While the Company reported “business under development” as a fifth operating segment in its previous Annual Report, management determined that this no longer met the definition of an operating segment. The Company will continually review its operations and reporting structure in order to disclose its operating segments.

Segment net revenue from external customers:

	For the three months ended August 31,
		2021		2020
Cannabis business	$	70,449	$	51,202
Distribution business		67,186		66,288
Beverage alcohol business		15,461		—
Wellness business		14,927		—
Total	$	168,023	$	117,490

Segment gross profit from external customers:

	For the three months ended August 31,
	2021		2020
Cannabis business	$	30,258	$	25,427
Distribution business		7,896		9,518
Beverage alcohol business		8,799		—
Wellness business		4,002		—
Total	$	50,955	$	34,945

Channels of Cannabis revenue were as follows:

	For the three months ended August 31,
	2021			2020
Revenue from medical cannabis products	$	8,374		$	6,380
Revenue from adult-use cannabis products		69,593			56,948
Revenue from wholesale cannabis products		1,700			3,792
Revenue from international cannabis products		10,266			—
Less excise taxes		(19,484	)		(15,918	)
Total	$	70,449		$	51,202

Geographic net revenue:

	For the three months ended August 31,
	2021		2020
North America	$	90,543	$	51,192
EMEA		76,009		65,077
Latin America		1,471		1,221
Total	$	168,023	$	117,490

Geographic capital assets:

	August 31, 2021		May 31, 2021
North America	$	477,278	$	504,575
EMEA		139,958		140,838
Latin America		4,103		5,285
Total	$	621,339	$	650,698

Major customers are defined as customers that each individually account for greater than 10% of the Company’s annual revenues. For the three months ended August 31, 2021 and 2020, there were no major customers representing greater than 10% of our annual revenues.

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8981-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8657-108599

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-URI http://asc.fasb.org/topic&trid=2134510

+ Details

Basis of presentation and summary of significant accounting policies (Policies)	3 Months Ended
	Aug. 31, 2021
Accounting Policies [Abstract]
Basis of consolidation	Basis of consolidation Subsidiaries are entities controlled by the Company. Control exists when the Company either has a controlling voting interest or is the primary beneficiary of a variable interest entity. The financial statements of subsidiaries are included in the consolidated financial statements from the date that control commences until the date that control ceases. A complete list of our subsidiaries that existed prior to our most recent year end is included in the Company's Annual Report for the year ended May 31, 2021 filed in Form 10-K with the U.S. Securities and Exchange Commission on July 28, 2021 (“Annual Report”). On August 13, 2021, the Company and other investors formed Superhero Acquisition L.P., a Delaware limited partnership, (“SH Acquisition”). SH Acquisition was formed for the purpose of acquiring approximately $165.8 principal amount of senior secured convertible notes (the “MM Notes”) originally issued by MedMen Enterprises Inc. (“MedMen”) and certain warrants (the “MM Warrants”) to acquire Class B subordinate voting shares of Medmen (the “MedMen Shares”) issued in connection with the original issuance of the MM Notes. The MM Notes mature on August 17, 2028. Pursuant to an Assignment and Assumption Agreement dated as of August 17, 2021, SH Acquisition completed its acquisition (the “MM Transaction”) of the MM Notes and MM Warrants from certain funds affiliated with Gotham Green Partners. As partial consideration for the MM Notes and MM Warrants, on September 17, 2021, the Company issued 9,817,061 shares of its common stock. The balance of the consideration for the MM Notes and MM Warrants was paid in cash by the other partners of SH Acquisition. The Company’s interest in SH Acquisition represents its right to 68% of the MM Notes and related MM Warrants held by SH Acquisition, which are convertible into approximately 21% of the MedMen Shares outstanding upon closing of the MM Transaction. The Company’s ability to convert the MM Notes and exercise the MM Warrants is dependent upon federal laws in the United States being amended to permit the general cultivation, distribution and possession of cannabis (a “Triggering Event”) or the Company’s waiver of the need for a Triggering Event and the receipt of any additional regulatory approvals. The Company is a limited partner under the SH Acquisition partnership agreement; however, material events conducted by the partnership require the approval of the Company, and, upon a Triggering Event, the Company has the ability to appoint two of the three members of the board of directors of the general partner of the partnership. As a result, we have consolidated SH Acquisition as a subsidiary of Tilray beginning on August 17, 2021. Additional information about the MM Transaction is included in Note 7, Long-term investments.
Long-term investments	Long-term investments Debt securities are classified as available-for-sale and are recorded at fair value and are subject to impairment testing. Other than impairment losses, unrealized gains and losses during the period, net of the related tax effect, are excluded from income and reflected in other comprehensive income (loss), and the cumulative effect is reported as a separate component of shareholders’ equity until realized. Upon sale, realized gain and losses are reported in net income. Debt securities are impaired when a decline in fair value is determined to be other-than-temporary. If the cost of an investment exceeds its fair value, the Company evaluates, among other factors, general market conditions, credit quality of debt instrument issuers, and the duration and extent to which the fair value is less than cost. Once a decline in fair value is determined to be other-than-temporary, an impairment charge is recorded in the statements of net loss and a new cost basis for the investment is established. The Company also evaluates whether there is a plan to sell the security or it is more likely than not that the Company will be required to sell the security before recovery. If neither of the conditions exist, then only the portion of the impairment loss attributable to credit loss is recorded in the statements of net loss and the remaining amount is recorded in other comprehensive income (loss). Investments in equity securities of entities over which the Company does not have a controlling financial interest or significant influence are accounted for at fair value. Equity investments without readily determinable fair values are measured at cost with adjustments for observable changes in price or impairments (referred to as the “measurement alternative”). In applying the measurement alternative, the Company performs a qualitative assessment on a quarterly basis and recognizes an impairment if there are sufficient indicators that the fair value of the equity investments are less than carrying values. Changes in value are recorded in the statement of net loss and comprehensive loss, within the line, “Non-operating income (expense)”. Investments in entities over which the Company does not have a controlling financial interest but has significant influence, are accounted for using the equity method, with the Company’s share of earnings or losses reported in earnings or losses from equity method investments on the statements of net loss and comprehensive loss. Equity method investments are recorded at cost, plus the Company’s share of undistributed earnings or losses, and impairment, if any, within “Interest in Equity Investees” on the balance sheets. The Company assesses investments in equity method investments when events or circumstances indicate that the carrying amount of the investment may be impaired. If it is determined that the current fair value of an equity method investment is less than the carrying value of the investment, the Company will assess if the shortfall is other than temporary (OTTI). Evidence of a loss in value might include, but would not necessarily be limited to, absence of an ability to recover the carrying amount of the investment or inability of the equity investee to sustain an earnings capacity that would justify the carrying amount of the investment. Once a determination is made that an OTTI exists, the investment is written down to its fair value in accordance with ASC 820 at the reporting date, which establishes a new cost basis.
New accounting pronouncements recently adopted/ not yet adopted	New accounting pronouncements not yet adopted In August 2020, the FASB issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”), which amends and simplifies existing guidance in an effort to reduce the complexity of accounting for convertible instruments and to provide financial statement users with more meaningful information. ASU 2020-06 is effective for the Company beginning June 1, 2022. This update may be applied retrospectively or on a modified retrospective basis with the cumulative effect recognized as an adjustment to the opening balance of retained earnings on the date of adoption. The Company is currently evaluating the effect of adopting this ASU. In May 2021, the FASB issued ASU 2021-04, Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40) (“ASU 2021-04”), which amends existing guidance for earnings per share (EPS) in accordance with Topic 260. ASU 2021-04 is effective for the Company beginning June 1, 2022. This update should be applied prospectively on or after the effective date of the amendments. The Company is currently evaluating the effect of adopting this ASU. New accounting pronouncements recently adopted In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740) – Simplifying the Accounting for Income Taxes (“ASU 2019-12”), which is intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. The standard is effective for annual reporting periods beginning after December 15, 2021 and including interim periods within those fiscal years. The Company adopted the ASU beginning June 1, 2021 and the adoption of ASU 2019-12 did not have a material impact on our consolidated financial statements. In January 2020, the FASB issued ASU 2020-01, Investments – Equity Securities (Topic 321), Investments - Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815) (“ASU 2020-01”), which is intended to clarify the interaction of the accounting for equity securities under Topic 321 and investments accounted for under the equity method of accounting in Topic 323 and the accounting for certain forward contracts and purchased options accounted for under Topic 815. The Company adopted the ASU beginning June 1, 2021 and the adoption of ASU 2020-01 did not have a material impact on our consolidated financial statements.

Inventory (Tables)

3 Months Ended

Aug. 31, 2021

Inventory Disclosure [Abstract]

Schedule of Inventory

Inventory is comprised of:

	August 31, 2021		May 31, 2021
Plants	$	19,605	$	23,083
Dried cannabis		113,180		118,269
Cannabis trim		3,448		2,931
Cannabis derivatives		38,613		24,158
Cannabis vapes		3,543		3,791
Packaging and other inventory items		25,595		31,462
Wellness inventory		14,042		15,171
Beverage alcohol inventory		4,796		5,402
Distribution inventory		28,685		32,162
Total	$	251,507	$	256,429

Capital assets (Tables)

3 Months Ended

Aug. 31, 2021

Property Plant And Equipment [Abstract]

Summary of Capital Asset

Capital asset consisted of the following:

	August 31, 2021			May 31, 2021
Land	$	31,467		$	28,549
Production facility		413,711			346,510
Equipment		231,290			215,408
Leasehold improvement		7,477			17,059
ROU-assets under finance lease		35,290			34,726
Construction in progress		19,174			85,322
	$	738,408		$	727,574
Less: accumulated amortization		(117,070	)		(76,876	)
Total	$	621,339		$	650,698

Intangible Assets (Tables)

3 Months Ended

Aug. 31, 2021

Intangible Assets Net Excluding Goodwill [Abstract]

Schedule of Intangible Assets

Intangible assets are comprised of the following items:

										Intellectual
	Customer									property,
	relationships			Licenses,			Non-			trademarks,			Total
	& distribution			permits &			compete			know how			intangible
	channel			applications			agreements			& brands			assets
Cost
At May 31, 2021	$	239,810		$	414,930		$	12,453		$	990,917		$	1,658,110
Additions		—			182			—			856			1,038
Effect of foreign exchange		(9,300	)		(17,346	)		(659	)		(51,738	)		(79,043	)
At August 31, 2021	$	230,510			397,766			11,794			940,035		$	1,580,105
Accumulated amortization
At May 31, 2021	$	18,302			1,167			4,299			28,424		$	52,192
Amortization		9,466		116			833				14,684			25,099
At August 31, 2021	$	27,768		$	1,283		$	5,132		$	43,108		$	77,291
Net book value at May 31, 2021	$	221,508		$	413,763		$	8,154		$	962,493		$	1,605,918
Net book value at August 31, 2021	$	202,742		$	396,483		$	6,662		$	896,927		$	1,502,814

Schedule of Estimated Amortization Expense

Expected future amortization expense for intangible assets as of August 31, 2021 are as follows:

	Amortization
2022 (remaining nine months)	$	48,820
2023		67,556
2024		64,084
2025		61,297
2026		61,297
Thereafter		791,760
Total	$	1,094,814

Goodwill (Tables)

3 Months Ended

Aug. 31, 2021

Goodwill Disclosure [Abstract]

Schedule of Change in Carrying Amount of Goodwill

The following table shows the change in the carrying amount of goodwill:

		August 31,		May 31,
	Segment	2021		2021
Broken Coast Cannabis Ltd.	Cannabis business	$	105,963	$	105,963
Nuuvera Corp.	Cannabis business		273,606		273,606
LATAM Holdings Inc.	Cannabis business		63,239		63,239
CC Pharma GmbH	Distribution business		4,458		4,458
SweetWater	Beverage alcohol business		100,202		100,202
Tilray	Cannabis business		2,144,143		2,144,143
Tilray	Wellness business		77,470		77,470
Effect of foreign exchange			40,050		63,713
Total		$	2,809,131	$	2,832,794

Long-term investments (Tables)

3 Months Ended

Aug. 31, 2021

Investments All Other Investments [Abstract]

Schedule of Long-term Investments

Long term investments are comprised of:

	August 31, 2021		May 31, 2021
Debt securities classified under available-for-sale method	$	170,799	$	—
Equity investments measured at fair value		10,108		12,185
Equity investments under measurement alternative		5,500		5,500
Total investments in debt and equity securities	$	186,407	$	17,685

Summary of Activity Related to Equity Investments

The following table summarizes the activity related to equity investments for the three months ended August 31, 2021.

			Changes in fair
	May 31, 2021		value recorded in			Sales / purchases /		August 31, 2021
	Carrying value		net loss			other		Carrying value
Debt securities classified under available-for-sale method	$	—		—			170,799	$	170,799
Equity investments with readily determinable value	$	12,185		(2,077	)		—	$	10,108
Equity investments without readily determinable value	$	5,500		—			—	$	5,500

Accounts payable and accrued liabilities (Tables)

3 Months Ended

Aug. 31, 2021

Payables And Accruals [Abstract]

Summary of Accounts Payable and Accrued Liabilities

Accounts payable and accrued liabilities are comprised of:

	August 31,		May 31,
	2021		2021
Trade payables	$	61,990	$	57,706
Accrued liabilities		85,977		112,594
Accrued payroll and employment related taxes		23,486		19,390
Income taxes payable		14,023		14,764
Accrued interest		3,440		148
Other accruals		1,297		8,211
Total	$	190,213	$	212,813

Long-term debt (Tables)

3 Months Ended

Aug. 31, 2021

Long Term Debt [Abstract]

Schedule of Net Carrying Amount of Long-term Debt Instruments

The following table sets forth the net carrying amount of long-term debt instruments:

	August 31,			May 31,
	2021			2021
Credit facility - C$80,000 - Canadian prime interest rate plus an applicable margin, 3-year term, with a 10-year amortization, repayable in blended monthly payments, due in November 2022	$	58,730		$	62,964
Term loan - C$25,000 - Canadian 5-year bond interest rate plus 2.73% with a minimum 4.50%, 5-year term, with a 15-year amortization, repayable in blended monthly payments, due in July 2023		13,454			14,335
Term loan - C$25,000 - 3.95%, compounded monthly, 5-year term with a 15-year amortization, repayable in equal monthly instalments of $188 including interest, due in April 2022		16,011			17,117
Term loan - C$1,250 - 3.85%, 5-year term, with a 10-year amortization, repayable in equal monthly instalments of $13 including interest, due in August 2026		538			587
Mortgage payable - C$3,750 - 3.85%, 5-year term, with a 20-year amortization, repayable in equal monthly instalments of $23 including interest, due in August 2026		2,425			2,562
Vendor take-back mortgage - C$2,850 - 6.75%, 5-year term, repayable in equal monthly instalments of $56 including interest, due in June 2021		-			92
Term loan ‐ €5,000 ‐ Euro Interbank Offered Rate + 1.79%, 5‐year term, repayable in quarterly instalments of €250 plus interest, due in December 2023		3,239			3,356
Term loan ‐ €5,000 ‐ Euro Interbank Offered Rate + 2.68%, 5‐year term, repayable in quarterly instalments of €250 plus interest, due in December 2023		3,239			3,356
Term loan ‐ €1,500 ‐ Euro Interbank Offered Rate + 2.00%, 5‐year term, repayable in quarterly instalments of €98 including interest, due in April 2025		1,767			1,831
Term loan ‐ €1,500 ‐ Euro Interbank Offered Rate + 2.00%, 5‐year term, repayable in quarterly instalments of €98 including interest, due in June 2025		1,767			1,831
Term loan - $100,000 - EUROBIR rate plus an applicable margin, 3-year term, repayable in quarterly instalments beginning March 31, 2021 of $7,500 in its first twelve months and $10,000 in each of the next two years, due in March 2024		96,250			98,138
Carrying amount of long-term debt		197,420			206,169
Unamortized financing fees		(1,672	)		(2,061	)
Net carrying amount		195,748			204,108
Less principal portion included in current liabilities		(30,837	)		(36,622	)
Total noncurrent portion of long-term debt	$	164,911		$	167,486

- Definition

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-04(a))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 55
-Paragraph 69B
-URI http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 55
-Paragraph 69E
-URI http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644

+ Details

Convertible debentures (Tables)

3 Months Ended

Aug. 31, 2021

Debt Instrument [Line Items]

Schedule of Estimated Fair Value of Convertible Debenture / Warrant Liability

The Company estimated the fair value of the Warrant liability at August 31, 2021 at $9.74 per warrant using the Black-Scholes pricing model (Level 3) with the following weighted-average assumptions:

Risk-free interest rate		0.84	%
Expected volatility		70	%
Expected term	4.05 years
Expected dividend yield		0.0	%
Strike price	$	5.95
Fair value of common stock	$	13.69

The unrealized gain (loss) on fair value for the Convertible Debenture and the warrant liability is recognized in non-operating income (loss) using the following inputs:

Financial asset / financial liability	Valuation technique	Significant unobservable input	Inputs
APHA Convertible debentures	Black-Scholes	Volatility, expected life	70% 3 years
Warrant liability	Black-Scholes	Volatility, expected life	70% 4 years
Contingent consideration	Discounted cash flows	Discount rate, achievement	5% 100%

Convertible Debentures

Debt Instrument [Line Items]

Summary of Convertible Notes Receivable

The following table sets forth the net carrying amount of the convertible debentures:

	August 31,		May 31,
	2021		2021
5.25% Convertible Notes ("APHA 24")	$	342,499	$	399,444
5.00% Convertible Notes ("TLRY 23")		269,147		268,180
Total	$	611,646	$	667,624

APHA 24

Debt Instrument [Line Items]

Summary of Convertible Notes Receivable

APHA 24

	August 31,			May 31,
	2021			2021
5.25% Contractual debenture	$	350,000		$	350,000
Debt settlement		(90,760	)		(90,760	)
Fair value adjustment		83,259			140,204
Net carrying amount of APHA 24	$	342,499		$	399,444

Schedule of Estimated Fair Value of Convertible Debenture / Warrant Liability

Risk-free interest rate		0.84	%
Expected volatility		70	%
Expected term	2.75 years
Expected dividend yield		0.0	%

TLRY 23

Debt Instrument [Line Items]

Summary of Convertible Notes Receivable

TLRY 23

	August 31,			May 31,
	2021			2021
5.00% Contractual debenture	$	277,856		$	277,856
Unamortized discount		(8,709	)		(9,676	)
Net carrying amount of TLRY 23	$	269,147		$	268,180

Warrant Liability (Tables)

3 Months Ended

Aug. 31, 2021

Warrants And Rights Note Disclosure [Abstract]

Schedule of Warrants Outstanding

Warrants outstanding at August 31, 2021:

			Balance						Balance
	Classification	Exercise Price	May 31, 2021		Issued		Exercised		August 31, 2021
Warrant – September 26, 2021	Equity	3.14		166,000		—		—		166,000
Warrant – January 30, 2022	Equity	9.26		5,828,651		—		—		5,828,651
Warrant – March 17, 2025	Liability	5.95		6,209,000		—		—		6,209,000
				12,203,651		—		—		12,203,651

	August 31, 2021				August 31, 2020
			Weighted				Weighted
	Number of		average		Number of		average
	warrants		price		warrants		price
Outstanding, opening		12,203,651	$	7.41		5,994,651	$	8.91
Exercised during the period		—		—		—		—
Issued during the period		—		—		—		—
Cancelled during the period		—		—		—		—
Expired during the period		—		—		—		—
Outstanding, ending		12,203,651	$	7.41		5,994,651	$	8.91

Schedule of Estimated Fair Value of Convertible Debenture / Warrant Liability

The Company estimated the fair value of the Warrant liability at August 31, 2021 at $9.74 per warrant using the Black-Scholes pricing model (Level 3) with the following weighted-average assumptions:

Risk-free interest rate		0.84	%
Expected volatility		70	%
Expected term	4.05 years
Expected dividend yield		0.0	%
Strike price	$	5.95
Fair value of common stock	$	13.69

The unrealized gain (loss) on fair value for the Convertible Debenture and the warrant liability is recognized in non-operating income (loss) using the following inputs:

Financial asset / financial liability	Valuation technique	Significant unobservable input	Inputs
APHA Convertible debentures	Black-Scholes	Volatility, expected life	70% 3 years
Warrant liability	Black-Scholes	Volatility, expected life	70% 4 years
Contingent consideration	Discounted cash flows	Discount rate, achievement	5% 100%

Stock-based compensation (Tables)

3 Months Ended

Aug. 31, 2021

Tilray 2018 Equity Incentive Plan and Original Plan | EIP Original Plan and Time-based RSU

Schedule of Stock Option Activity

Stock-based activity under the EIP and Original Plan for the year ended August 31, 2021 is as follows:

EIP Time-based stock option activity
						Weighted-
				Weighted-		average
				average		remaining
	Stock			exercise		contractual		Aggregate
	Options			price		term (years)		intrinsic value
Balance, May 31, 2021		3,180,226		$	14.19	1.3		$	25,171
Granted		—			—		—		—
Exercised		(67,750	)		7.76		—		—
Forfeited		(112,306	)		21.40		—		—
Cancelled		(2,498	)		65.20		—		—
Balance, August 31, 2021		2,997,672		$	14.02	6.5		$	15,843

Original plan time-based stock option activity
						Weighted-
				Weighted-		average
				average		remaining
	Stock			exercise		contractual		Aggregate
	Options			price		term (years)		intrinsic value
Balance, May 31, 2021		917,545		$	3.97	1.7		$	11,886
Exercised		(411,742	)		3.41		—		—
Forfeited		(4,250	)		4.79		—		—
Cancelled		(16,093	)		26.30		—		—
Balance, August 31, 2021		485,460		$	3.69		2.7	$	4,954

EIP Time-based RSU activity
				Weighted- average		Weighted- average
				grant-date		remaining
	Time-based			fair value		contractual		Aggregate
	RSUs			per share		term (years)		intrinsic value
Balance, May 31, 2021		1,205,243		$	15.16		—	$	20,091
Granted		981,229			14.39		—		—
Vested		(126,393	)		19.52		—		—
Forfeited		(121,295	)		16.39		—		—
Cancelled		—			—		—		—
Balance, August 31, 2021		1,938,784		$	14.41		—	$	28,709

EIP Performance-based RSU activity
			Weighted- average		Weighted- average
			grant-date		remaining
	Performance-based		fair value		contractual		Aggregate
	RSUs		per share		term (years)		intrinsic value
Balance, May 31, 2021		—	$	—		—	$	—
Granted		1,345,158		13.13		—		17,668
Vested		—		—		—		—
Forfeited		—		—		—		—
Cancelled		—		—		—		—
Balance, August 31, 2021		1,345,158	$	13.13		2.9	$	17,668

Predecessor Plan | Time-based Stock Options | Aphria

Schedule of Stock Option Activity

Stock option, RSU and DSU activity for the Company under the Predecessor Plan is as follows:

Predecessor plan time-based stock option activity

	August 31, 2021
						Weighted		Weighted
				Weighted		average		average
				average		grant		remaining		Aggregate
	Number of			exercise		date fair		contractual		Intrinsic
	options			price		value		term (years)		Amount
Balance May 31, 2021		2,499,185		$	12.48	$	6.51		2.4		(10,472	)
Granted		—			—		—		—		—
Exercised		(56,301	)		9.34		4.50		—		—
Forfeited		(638	)		8.95		4.15		—		—
Expired		(405,455	)		19.94		9.29		—		—
Balance, August 31, 2021		2,036,790		$	11.08	$	6.02		2.67	$	5,321
Vested and exercisable, August 31, 2021		1,821,178		$	11.17	$	6.10		2.65	$	4,588

Predecessor Plan | Time-based and Performance-based RSU | Aphria

Schedule of Time-based and Performance-based RSU Activity

Predecessor plan time-based and Performance-based RSU activity

	August 31, 2021
				Weighted				Weighted
				average				average
				grant -				grant -
				date fair		Performance-		date fair
	Time- based			value per		based		value per
	RSUs			share		RSUs		share
Balance, May 31, 2021		2,794,972		$	6.88		—		—
Granted		—			—		—		—
Exercised		(1,574,381	)		6.56		—		—
Forfeited		(46,171	)		15.09		—		—
Balance, August 31, 2021		1,174,419		$	6.98		—		—

Accumulated other comprehensive income (loss) (Tables)

3 Months Ended

Aug. 31, 2021

Equity [Abstract]

Schedule of Accumulated Other Comprehensive Loss

Accumulated other comprehensive loss includes the following components:

	Foreign currency translation gain (loss)			Unrealized loss on convertible notes receivables			Total
Balance May 31, 2021	$	156,417		$	(3,749	)	$	152,668
Other comprehensive loss		(100,772	)		(649	)		(101,421	)
Balance August 31, 2021	$	55,645		$	(4,398	)	$	51,247

Non-controlling interests (Tables)

3 Months Ended

Aug. 31, 2021

Text Block [Abstract]

Summary of Information Relating to Company's Subsidiaries

The following tables summarize the information relating to the Company’s subsidiaries, Superhero LP, CC Pharma Nordic ApS, Aphria Diamond, and ColCanna S.A.S. before intercompany eliminations.

Non-controlling interests as of August 31, 2021:

	Superhero			CC Pharma			Aphria			ColCanna			August 31,
	LP			Nordic ApS			Diamond			S.A.S.			2021
Current assets	$	52,995		$	951		$	26,058		$	527		$	80,531
Non-current assets		170,799			132			156,839			141,387			469,157
Current liabilities		(170,799	)		(1,033	)		(16,047	)		(66	)		(187,945	)
Non-current liabilities		—			(392	)		(80,543	)		(23,581	)		(104,516	)
Net assets	$	52,995		$	(343	)	$	86,307		$	118,267		$	257,227

Non-controlling interests as of May 31, 2021:

	CC Pharma			Aphria			ColCanna			May 31,
	Nordic ApS			Diamond			S.A.S.			2021
Current assets	$	919		$	19,531		$	315		$	20,765
Non-current assets		103			153,696			146,587			300,386
Current liabilities		(956	)		(28,511	)		(62	)		(29,529	)
Non-current liabilities		(406	)		(69,332	)		(6,606	)		(76,344	)
Net assets	$	(340	)	$	75,384		$	140,234		$	215,278

Non-controlling interests for the three months ended August 31, 2021:

	Superhero		CC Pharma			Aphria		ColCanna			August 31,
	LP		Nordic ApS			Diamond		S.A.S.			2021
Revenue	$	—	$	—		$	20,325	$	—		$	20,325
Total expenses		—		4			13,274		2			13,280
Net (loss) income		—		(4	)		7,051		(2	)		7,045
Other comprehensive (loss) income		—		—			—		—			—
Net comprehensive income	$	—	$	(4	)	$	7,051	$	(2	)	$	7,045

Non-controlling interests for the three months ended August 31, 2020:

	CC Pharma		Aphria		ColCanna			August 31,
	Nordic ApS		Diamond		S.A.S.			2020
Revenue	$	—	$	30,035	$	—		$	30,035
Total expenses (recovery)		—		17,675		(239	)		17,436
Net (loss) income		—		12,360		239			12,599
Other comprehensive (loss) income		—		—		—			—
Net comprehensive income	$	—	$	12,360	$	239		$	12,599

Commitments and contingencies (Tables)

3 Months Ended

Aug. 31, 2021

Commitments And Contingencies Disclosure [Abstract]

Schedule of Purchase and Other Commitments Maturities

	Total		2022 (remaining nine months)		2023		2024		2025		2026		Thereafter
Long-term debt repayment	$	198,253	$	32,981	$	78,820	$	80,838	$	2,157	$	2,516	$	941
Convertible notes, principal and interest		571,989		13,893		13,893		284,803		259,400		—		—
ABG finance liability		6,000		1,500		1,500		1,500		1,500		—		—
Material purchase obligations		29,523		24,222		4,185		937		179		—		—
Construction commitments		2,012		2,012		—		—		—		—		—
Total	$	807,776	$	74,608	$	98,398	$	368,077	$	263,236	$	2,516	$	941

Summary of Future Undiscounted Payment Associated with Lease Liabilities

The following table presents the future undiscounted payment associated with lease liabilities as of August 31, 2021:

	Operating			Finance
	leases			leases
2022 (remaining nine months)		3,832			1,672
2023		4,437			7,088
2024		3,840			2,061
2025		3,321			2,122
2026		3,472			2,186
Thereafter		8,522			39,586
Total minimum lease payments	$	27,423		$	54,715
Imputed interest		(5,778	)		(19,167	)
Obligations recognized	$	21,645		$	35,548

Net revenue (Tables)

3 Months Ended

Aug. 31, 2021

Revenues [Abstract]

Summary of Net Revenue

Net revenue is comprised of:

	For the three months ended August 31.
	2021			2020
Cannabis revenue	$	89,933		$	67,120
Cannabis excise taxes		(19,484	)		(15,918	)
Net cannabis revenue		70,449			51,202
Beverage alcohol revenue		16,483			—
Beverage alcohol excise taxes		(1,022	)		—
Net beverage alcohol revenue		15,461			—
Distribution revenue		67,186			66,288
Wellness revenue		14,927			—
Total	$	168,023		$	117,490

Cost of Goods Sold (Tables)

3 Months Ended

Aug. 31, 2021

Cost Of Goods And Services Sold [Abstract]

Summary of Cost of Goods Sold

Cost of goods sold is comprised of:

	For the three months ended August 31,
	2021		2020
Cannabis costs	$	40,190	$	25,775
Beverage alcohol costs		6,662		—
Distribution costs		59,290		56,770
Wellness costs		10,925		—
Total	$	117,068	$	82,545

General and administrative expenses (Tables)

3 Months Ended

Aug. 31, 2021

General And Administrative Expense [Abstract]

Schedule of General and Administrative Expenses

General and administrative expenses are comprised of:

	For the three months ended August 31,
	2021		2020
Executive compensation	$	3,090	$	2,250
Office and general		12,769		4,421
Salaries and wages		15,311		9,343
Stock-based compensation		9,417		2,850
Insurance		4,631		3,206
Professional fees		2,713		2,935
Travel and accommodation		790		727
Rent		766		240
Total	$	49,487	$	25,972

Non-operating income (expense) (Tables)

3 Months Ended

Aug. 31, 2021

Nonoperating Income Expense [Abstract]

Schedule of Non-Operating Income (Expense)

Non-operating income (expense) is comprised of:

	For the three months ended August 31,
	2021			2020
Change in fair value of convertible debenture	$	39,370		$	340
Change in fair value of warrant liability		17,535			—
Foreign exchange loss		(5,724	)		(16,331	)
Loss on long-term investments		(1,675	)		(1,120	)
Gain from equity investees		1,356			—
Other non-operating (losses) gains, net		(2,002	)		3,752
Total	$	48,860		$	(13,359	)

Financial risk management and financial instruments (Tables)

3 Months Ended

Aug. 31, 2021

Financial Risk Management And Financial Instruments [Abstract]

Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis

							August 31,
	Level 1		Level 2		Level 3		2021
Financial assets
Cash and cash equivalents	$	376,297	$	—	$	—	$	376,297
Convertible notes receivable		—		2,370		—		2,370
Long-term investments		7,174		173,733		—		180,907
Financial liabilities
Warrant liability		—		—		60,476		60,476
Contingent consideration		—		—		61,494		61,494
APHA 24 Convertible debenture		—		—		342,499		342,499
Total recurring fair value measurements	$	383,471	$	176,103	$	464,468	$	1,024,042

							May 31,
	Level 1		Level 2		Level 3		2021
Financial assets
Cash and cash equivalents	$	488,466	—		—		$	488,466
Convertible notes receivable	—			2,485	—			2,485
Long-term investments		9,251		2,934	—			12,185
Financial liabilities
Warrant liability	—		—			78,168		78,168
Contingent consideration	—		—			60,657		60,657
APHA 24 Convertible debenture	—		—			399,444		399,444
Total recurring fair value measurements	$	497,717	$	5,419	$	538,269	$	1,041,405

Schedule of Balances of Assets and Liabilities Categorized Within Level 3 of Fair Value Hierarchy Measured at Fair Value on Recurring Basis

The balances of assets and liabilities categorized within Level 3 of the fair value hierarchy measured at fair value on a recurring basis are reconciled, as follows:

	APHA 24
	Convertible			Warrant			Contingent
	Debt			Liability			Consideration			Total
Balance, May 31, 2021		(399,444	)		(78,168	)		(60,657	)		(538,269	)
Additions		—			—			—			—
Disposals		—			—			—			—
Unrealized gain (loss) on fair value		56,945			17,692			(837	)		73,800
Balance, August 31, 2021		(342,499	)		(60,476	)		(61,494	)		(464,469	)

Schedule of Estimated Fair Value of Convertible Debenture / Warrant Liability

The Company estimated the fair value of the Warrant liability at August 31, 2021 at $9.74 per warrant using the Black-Scholes pricing model (Level 3) with the following weighted-average assumptions:

Risk-free interest rate		0.84	%
Expected volatility		70	%
Expected term	4.05 years
Expected dividend yield		0.0	%
Strike price	$	5.95
Fair value of common stock	$	13.69

The unrealized gain (loss) on fair value for the Convertible Debenture and the warrant liability is recognized in non-operating income (loss) using the following inputs:

Financial asset / financial liability	Valuation technique	Significant unobservable input	Inputs
APHA Convertible debentures	Black-Scholes	Volatility, expected life	70% 3 years
Warrant liability	Black-Scholes	Volatility, expected life	70% 4 years
Contingent consideration	Discounted cash flows	Discount rate, achievement	5% 100%

- Definition

Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.

+ References + Details

Segment reporting (Tables)

3 Months Ended

Aug. 31, 2021

Segment Reporting [Abstract]

Schedule of Segment Net Revenue From External Customers

Segment net revenue from external customers:

	For the three months ended August 31,
		2021		2020
Cannabis business	$	70,449	$	51,202
Distribution business		67,186		66,288
Beverage alcohol business		15,461		—
Wellness business		14,927		—
Total	$	168,023	$	117,490

Channels of Cannabis revenue were as follows:

	For the three months ended August 31,
	2021			2020
Revenue from medical cannabis products	$	8,374		$	6,380
Revenue from adult-use cannabis products		69,593			56,948
Revenue from wholesale cannabis products		1,700			3,792
Revenue from international cannabis products		10,266			—
Less excise taxes		(19,484	)		(15,918	)
Total	$	70,449		$	51,202

Schedule of Segment Gross Profit From External Customers

Segment gross profit from external customers:

	For the three months ended August 31,
	2021		2020
Cannabis business	$	30,258	$	25,427
Distribution business		7,896		9,518
Beverage alcohol business		8,799		—
Wellness business		4,002		—
Total	$	50,955	$	34,945

Schedule of Geographic Net Revenue

Geographic net revenue:

	For the three months ended August 31,
	2021		2020
North America	$	90,543	$	51,192
EMEA		76,009		65,077
Latin America		1,471		1,221
Total	$	168,023	$	117,490

Schedule of Geographic Capital Assets

Geographic capital assets:

	August 31, 2021		May 31, 2021
North America	$	477,278	$	504,575
EMEA		139,958		140,838
Latin America		4,103		5,285
Total	$	621,339	$	650,698

Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details) - USD ($)	Sep. 17, 2021	Aug. 13, 2021
Subsequent Event
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Common stock issued, shares	9,817,061
SH Acquisition
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Convertible notes conversion percentage of shares		21.00%
SH Acquisition \| Subsequent Event
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Common stock issued, shares	9,817,061
MM Notes \| Convertible Senior Notes Due 2028 \| SH Acquisition
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Principal amount of senior secured convertible notes		$ 165,800
Debt instrument maturity date		Aug. 17, 2028
MM Notes and MM Warrants \| SH Acquisition
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Acquisition of equity ownership percentage		68.00%

Inventory - Schedule of Inventory (Details) - USD ($) $ in Thousands	Aug. 31, 2021	May 31, 2021
Inventory [Line Items]
Total	$ 251,507	$ 256,429
Plants
Inventory [Line Items]
Total	19,605	23,083
Dried Cannabis
Inventory [Line Items]
Total	113,180	118,269
Cannabis Trim
Inventory [Line Items]
Total	3,448	2,931
Cannabis Derivatives
Inventory [Line Items]
Total	38,613	24,158
Cannabis Vapes
Inventory [Line Items]
Total	3,543	3,791
Packaging and Other Inventory Items
Inventory [Line Items]
Total	25,595	31,462
Wellness Inventory
Inventory [Line Items]
Total	14,042	15,171
Beverage Alcohol Inventory
Inventory [Line Items]
Total	4,796	5,402
Distribution Inventory
Inventory [Line Items]
Total	$ 28,685	$ 32,162

Capital Assets - Schedule of Capital Assets (Details) - USD ($) $ in Thousands	Aug. 31, 2021	May 31, 2021
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 738,408	$ 727,574
Less: accumulated amortization	(117,070)	(76,876)
Total	621,339	650,698
Land
Property Plant And Equipment [Line Items]
Property and equipment, gross	31,467	28,549
Production Facility
Property Plant And Equipment [Line Items]
Property and equipment, gross	413,711	346,510
Equipment
Property Plant And Equipment [Line Items]
Property and equipment, gross	231,290	215,408
Leasehold Improvements
Property Plant And Equipment [Line Items]
Property and equipment, gross	7,477	17,059
ROU Assets Under Finance Lease
Property Plant And Equipment [Line Items]
Property and equipment, gross	35,290	34,726
Construction in Progress
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 19,174	$ 85,322

Intangible Assets - Schedule of Intangible Assets (Details) - USD ($) $ in Thousands	3 Months Ended
	Aug. 31, 2021	May 31, 2021
Finite Lived Intangible Assets [Line Items]
Intangible assets, Cost	$ 1,658,110
Additions	1,038
Effect of foreign exchange	(79,043)
Intangible assets, Cost	1,580,105
Intangible assets, Accumulated depreciation	52,192
Amortization	25,099
Intangible assets, Accumulated depreciation	77,291
Intangible assets, Net book value	1,502,814	$ 1,605,918
Customer Relationships and Distribution Channel
Finite Lived Intangible Assets [Line Items]
Intangible assets, Cost	239,810
Effect of foreign exchange	(9,300)
Intangible assets, Cost	230,510
Intangible assets, Accumulated depreciation	18,302
Amortization	9,466
Intangible assets, Accumulated depreciation	27,768
Intangible assets, Net book value	202,742	221,508
Licences, Permits & Applications
Finite Lived Intangible Assets [Line Items]
Intangible assets, Cost	414,930
Additions	182
Effect of foreign exchange	(17,346)
Intangible assets, Cost	397,766
Intangible assets, Accumulated depreciation	1,167
Amortization	116
Intangible assets, Accumulated depreciation	1,283
Intangible assets, Net book value	396,483	413,763
Non-compete Agreements
Finite Lived Intangible Assets [Line Items]
Intangible assets, Cost	12,453
Effect of foreign exchange	(659)
Intangible assets, Cost	11,794
Intangible assets, Accumulated depreciation	4,299
Amortization	833
Intangible assets, Accumulated depreciation	5,132
Intangible assets, Net book value	6,662	8,154
Intellectual Property, Trademarks, Know How & Brands
Finite Lived Intangible Assets [Line Items]
Intangible assets, Cost	990,917
Additions	856
Effect of foreign exchange	(51,738)
Intangible assets, Cost	940,035
Intangible assets, Accumulated depreciation	28,424
Amortization	14,684
Intangible assets, Accumulated depreciation	43,108
Intangible assets, Net book value	$ 896,927	$ 962,493

Intangible Assets - Additional Information (Details) - USD ($) $ in Thousands	Aug. 31, 2021	May 31, 2021
Licences, Permits & Applications
Indefinite Lived Intangible Assets By Major Class [Line Items]
Indefinite lived intangible assets	$ 408,000	$ 412,000

Intangible Assets - Schedule of Estimated Amortization Expense (Details) $ in Thousands	Aug. 31, 2021 USD ($)
Finite Lived Intangible Assets Future Amortization Expense [Abstract]
2022 (remaining nine months)	$ 48,820
2023	67,556
2024	64,084
2025	61,297
2026	61,297
Thereafter	791,760
Total	$ 1,094,814

Goodwill - Schedule of Goodwill (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Aug. 31, 2021	May 31, 2021
Goodwill [Line Items]
Effect of foreign exchange	$ 40,050	$ 63,713
Total	2,809,131	2,832,794
Broken Coast Cannabis Ltd. \| Cannabis Business
Goodwill [Line Items]
Goodwill, acquired during period	105,963	105,963
Nuuvera Corp. \| Cannabis Business
Goodwill [Line Items]
Goodwill, acquired during period	273,606	273,606
LATAM Holdings Inc. \| Cannabis Business
Goodwill [Line Items]
Goodwill, acquired during period	63,239	63,239
CC Pharma GmbH \| Distribution Business
Goodwill [Line Items]
Goodwill, acquired during period	4,458	4,458
Sweet Water \| Beverage Alcohol Business
Goodwill [Line Items]
Goodwill, acquired during period	100,202	100,202
Tilray \| Cannabis Business
Goodwill [Line Items]
Goodwill, acquired during period	2,144,143	2,144,143
Tilray \| Hemp Business
Goodwill [Line Items]
Goodwill, acquired during period	$ 77,470	$ 77,470

Long-term Investments - Schedule of Long-term Investments (Details) - USD ($) $ in Thousands	Aug. 31, 2021	May 31, 2021
Investments Debt And Equity Securities [Abstract]
Debt securities classified under available-for-sale method	$ 170,799
Equity investments measured at fair value	10,108	$ 12,185
Equity investments under measurement alternative	5,500	5,500
Total investments in debt and equity securities	$ 186,407	$ 17,685

Long-term Investments - Additional Information (Details) - MM Notes	3 Months Ended
	Aug. 31, 2021
Schedule Of Available For Sale Securities [Line Items]
Convertible debt instruments contractual maturity	2028
LIBOR
Schedule Of Available For Sale Securities [Line Items]
Interest rate	6.00%
LIBOR \| Floor
Schedule Of Available For Sale Securities [Line Items]
Interest rate	2.50%

Long-term Investments - Summary of Activity Related to Equity Investments (Details) $ in Thousands	3 Months Ended
	Aug. 31, 2021 USD ($)
Schedule Of Available For Sale Securities [Line Items]
Carrying value, ending balance	$ 170,799
Debt Securities Classified Under Available-for-sale Method
Schedule Of Available For Sale Securities [Line Items]
Sales / purchases / other	170,799
Carrying value, ending balance	170,799
Equity Investments With Readily Determinable Value
Schedule Of Available For Sale Securities [Line Items]
Carrying value, beginning balance	12,185
Changes in fair value recorded in net loss	(2,077)
Carrying value, ending balance	10,108
Equity Investments Without Readily Determinable Value
Schedule Of Available For Sale Securities [Line Items]
Carrying value, beginning balance	5,500
Carrying value, ending balance	$ 5,500

Accounts Payable and Accrued Liabilities - Summary of Accounts Payable and Accrued Liabilities (Details) - USD ($) $ in Thousands	Aug. 31, 2021	May 31, 2021
Accounts Payable And Accrued Liabilities Current And Noncurrent [Abstract]
Trade payables	$ 61,990	$ 57,706
Accrued liabilities	85,977	112,594
Accrued payroll and employment related taxes	23,486	19,390
Income taxes payable	14,023	14,764
Accrued interest	3,440	148
Other accruals	1,297	8,211
Total	$ 190,213	$ 212,813

Bank Indebtedness - Additional Information (Details)	3 Months Ended
Bank Indebtedness - Additional Information (Details)	Aug. 31, 2021 CAD ($) Lineofcredit	Aug. 31, 2021 EUR (€) Lineofcredit	Aug. 31, 2021 USD ($)	Aug. 31, 2021 CAD ($)	Aug. 31, 2021 EUR (€)
Line Of Credit Facility [Line Items]
Operating line of credit	$ 1,000
Line of credit			$ 0
CC Pharma
Line Of Credit Facility [Line Items]
Line of credit				$ 8,413	€ 7,000
Number of operating lines of credit \| Lineofcredit	2	2
Available credit amount \| €		€ 8,500
Four Twenty Corporation (“420”) \| Revolving Credit Facility
Line Of Credit Facility [Line Items]
Line of credit			$ 0
Operating Lines of Credit One \| CC Pharma
Line Of Credit Facility [Line Items]
Operating line of credit \| €		5,000
Operating Lines of Credit Two \| CC Pharma
Line Of Credit Facility [Line Items]
Operating line of credit \| €		€ 3,500
Prime Rate
Line Of Credit Facility [Line Items]
Interest rate	7.50%	7.50%
Euro Over Night Index Average Plus \| Operating Lines of Credit One \| CC Pharma
Line Of Credit Facility [Line Items]
Interest rate			1.79%	1.79%	1.79%
Interest rate			1.79%	1.79%	1.79%
Euro Interbank Offered Rate Plus \| Operating Lines of Credit Two \| CC Pharma
Line Of Credit Facility [Line Items]
Interest rate			3.682%	3.682%	3.682%
Interest rate			3.682%	3.682%	3.682%
EURIBOR \| Four Twenty Corporation (“420”) \| Revolving Credit Facility
Line Of Credit Facility [Line Items]
Line of credit			$ 20,000,000

Long-term Debt - Schedule of Net Carrying Amount of Long-term Debt Instruments (Details) - USD ($) $ in Thousands	Aug. 31, 2021	May 31, 2021
Debt Instrument [Line Items]
Carrying amount of long-term debt	$ 197,420	$ 206,169
Unamortized financing fees	(1,672)	(2,061)
Net carrying amount	195,748	204,108
Less principal portion included in current liabilities	(30,837)	(36,622)
Total noncurrent portion of long-term debt	164,911	167,486
Credit Facility Due in November 2022
Debt Instrument [Line Items]
Carrying amount of long-term debt	58,730	62,964
Term Loan Due in July 2023
Debt Instrument [Line Items]
Carrying amount of long-term debt	13,454	14,335
Term Loan Due in April 2022
Debt Instrument [Line Items]
Carrying amount of long-term debt	16,011	17,117
Term Loan Due in August 2026
Debt Instrument [Line Items]
Carrying amount of long-term debt	538	587
Mortgage Payable due in August 2026
Debt Instrument [Line Items]
Carrying amount of long-term debt	2,425	2,562
Vendor-Take-Back Mortgage Due in June 2021
Debt Instrument [Line Items]
Carrying amount of long-term debt		92
Term Loan Due in December 2023 \| Euro Interbank Offered Rate + 1.79%
Debt Instrument [Line Items]
Carrying amount of long-term debt	3,239	3,356
Term Loan Due in December 2023 \| Euro Interbank Offered Rate + 2.68%
Debt Instrument [Line Items]
Carrying amount of long-term debt	3,239	3,356
Term Loan Due in April 2025 \| Euro Interbank Offered Rate + 2.00%
Debt Instrument [Line Items]
Carrying amount of long-term debt	1,767	1,831
Term Loan Due in June 2025 \| Euro Interbank Offered Rate + 2.00%
Debt Instrument [Line Items]
Carrying amount of long-term debt	1,767	1,831
Term Loan Due in March 2024 \| EURIBOR
Debt Instrument [Line Items]
Carrying amount of long-term debt	$ 96,250	$ 98,138

Long-term Debt - Schedule of Net Carrying Amount of Long-term Debt Instruments (Parenthetical) (Details) € in Thousands, $ in Thousands, $ in Thousands	3 Months Ended
	Aug. 31, 2021 USD ($)	Aug. 31, 2021 EUR (€)	Aug. 31, 2021 CAD ($)	Aug. 31, 2021 EUR (€)
Credit Facility Due in November 2022 \| Canadian Prime Interest Rate
Debt Instrument [Line Items]
Credit facility amount			$ 80,000
Debt instrument term	3 years	3 years
Debt instrument amortization period	10 years	10 years
Term Loan Due in July 2023 \| Canadian Five Year Bond Interest Rate Plus 2.73
Debt Instrument [Line Items]
Credit facility amount			$ 25,000
Debt instrument term	5 years	5 years
Debt instrument amortization period	15 years	15 years
Debt instrument interest rate percentage	2.73%		2.73%	2.73%
Term Loan Due in July 2023 \| Canadian Five Year Bond Interest Rate Plus 2.73 \| Minimum [Member]
Debt Instrument [Line Items]
Debt instrument interest rate percentage	4.50%		4.50%	4.50%
Term Loan Due in April 2022
Debt Instrument [Line Items]
Credit facility amount			$ 25,000
Debt instrument term	5 years	5 years
Debt instrument amortization period	15 years	15 years
Debt instrument interest rate percentage	3.95%		3.95%	3.95%
Repayment of instalments including interest	$ 188
Term Loan Due in August 2026
Debt Instrument [Line Items]
Credit facility amount			$ 1,250
Debt instrument term	5 years	5 years
Debt instrument amortization period	10 years	10 years
Debt instrument interest rate percentage	3.85%		3.85%	3.85%
Repayment of instalments including interest	$ 13
Mortgage Payable due in August 2026
Debt Instrument [Line Items]
Credit facility amount			$ 3,750
Debt instrument term	5 years	5 years
Debt instrument amortization period	20 years	20 years
Debt instrument interest rate percentage	3.85%		3.85%	3.85%
Repayment of instalments including interest	$ 23
Vendor-Take-Back Mortgage Due in June 2021
Debt Instrument [Line Items]
Credit facility amount			$ 2,850
Debt instrument term	5 years	5 years
Debt instrument interest rate percentage	6.75%		6.75%	6.75%
Repayment of instalments including interest	$ 56
Term Loan Due in December 2023 \| Euro Interbank Offered Rate + 1.79%
Debt Instrument [Line Items]
Credit facility amount \| €				€ 5,000
Debt instrument term	5 years	5 years
Debt instrument interest rate percentage	1.79%		1.79%	1.79%
Repayment of instalments including interest \| €		€ 250
Term Loan Due in December 2023 \| Euro Interbank Offered Rate + 2.68%
Debt Instrument [Line Items]
Credit facility amount \| €				€ 5,000
Debt instrument term	5 years	5 years
Debt instrument interest rate percentage	2.68%		2.68%	2.68%
Repayment of instalments including interest \| €		€ 250
Term Loan Due in April 2025 \| Euro Interbank Offered Rate + 2.00%
Debt Instrument [Line Items]
Credit facility amount \| €				€ 1,500
Debt instrument term	5 years	5 years
Debt instrument interest rate percentage	2.00%		2.00%	2.00%
Repayment of instalments including interest \| €		€ 98
Term Loan Due in June 2025 \| Euro Interbank Offered Rate + 2.00%
Debt Instrument [Line Items]
Credit facility amount \| €				€ 1,500
Debt instrument term	5 years	5 years
Debt instrument interest rate percentage	2.00%		2.00%	2.00%
Repayment of instalments including interest \| €		€ 98
Term Loan Due in March 2024 \| EURIBOR
Debt Instrument [Line Items]
Credit facility amount	$ 100,000
Debt instrument term	3 years	3 years
Long-term debt, repayments of principal in next rolling twelve months	$ 7,500
Long-term debt, repayments of principal in rolling year two	10,000
Long-term debt, repayments of principal in rolling year three	$ 10,000

Convertible Debentures - Schedule of Components of Net Carrying Amount of Convertible Debentures (Detail) - USD ($) $ in Thousands	Aug. 31, 2021	May 31, 2021
Debt Instrument [Line Items]
Total	$ 611,646	$ 667,624
5.25% Convertible Notes ("APHA 24")
Debt Instrument [Line Items]
Total	342,499	399,444
5.00% Convertible Notes ("TLRY 23")
Debt Instrument [Line Items]
Total	$ 269,147	$ 268,180

Convertible Debentures - Schedule of Convertible Debentures - APHA 24 (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Aug. 31, 2021	May 31, 2021
Debt Instrument [Line Items]
Opening balance	$ 667,624
Closing balance	611,646	$ 667,624
5.25% Convertible Notes ("APHA 24")
Debt Instrument [Line Items]
Opening balance	399,444
Debt settlement	(90,760)	(90,760)
Fair value adjustment	83,259	140,204
Closing balance	342,499	399,444
5.25% Convertible Notes ("APHA 24") \| 5.25% Contractual Debenture
Debt Instrument [Line Items]
Opening balance	$ 350,000	350,000
Closing balance		$ 350,000

Convertible Debentures - Additional Information (Details)	3 Months Ended
	Aug. 31, 2021
Debt Instruments [Abstract]
Estimated fair value of APHA 24 convertible debenture per convertible debenture	1,321

Convertible Debentures - Schedule of Estimated Fair Value of Convertible Debenture (Details)	Aug. 31, 2021 yr
Expected Term
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Measurement input	3
APHA 24 \| Level 3 \| Risk-free Interest Rate
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Measurement input	0.84
APHA 24 \| Level 3 \| Expected Volatility
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Measurement input	70
APHA 24 \| Level 3 \| Expected Term
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Measurement input	2.75
APHA 24 \| Level 3 \| Expected Dividend Yield
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Measurement input	0.0

Convertible Debentures - Schedule of Convertible Debentures - TLRY 23 (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Aug. 31, 2021	May 31, 2021
Debt Instrument [Line Items]
Opening balance	$ 667,624
Closing balance	611,646	$ 667,624
5.00% Convertible Notes ("TLRY 23")
Debt Instrument [Line Items]
Opening balance	268,180
Unamortized discount	(8,709)	(9,676)
Closing balance	269,147	268,180
5.00% Convertible Notes ("TLRY 23") \| 5.25% Contractual Debenture
Debt Instrument [Line Items]
Opening balance	$ 277,856	277,856
Closing balance		$ 277,856

Warrant Liability - Schedule of Warrant Details (Details) - $ / shares	3 Months Ended
	Aug. 31, 2021	Aug. 31, 2020	May 31, 2021	May 31, 2020
Class Of Warrant Or Right [Line Items]
Exercise Price	$ 7.41	$ 8.91	$ 7.41	$ 8.91
Beginning Balance	12,203,651	5,994,651
Issued	0	0
Exercised	0	0
Ending Balance	12,203,651	5,994,651
Warrant Expiring September 26, 2021
Class Of Warrant Or Right [Line Items]
Classification	Equity
Exercise Price	$ 3.14
Beginning Balance	166,000
Ending Balance	166,000
Warrant Expiring January 30, 2022
Class Of Warrant Or Right [Line Items]
Classification	Equity
Exercise Price	$ 9.26
Beginning Balance	5,828,651
Ending Balance	5,828,651
Warrant Expiring March 17, 2025
Class Of Warrant Or Right [Line Items]
Classification	Liability
Exercise Price	$ 5.95
Beginning Balance	6,209,000
Ending Balance	6,209,000

Warrant Liability - Schedule of Warrants Outstanding (Details) - $ / shares	3 Months Ended
	Aug. 31, 2021	Aug. 31, 2020
Warrants And Rights Note Disclosure [Abstract]
Beginning Balance	12,203,651	5,994,651
Exercised during the period, Number of warrants	0	0
Issued during the period, Number of warrants	0	0
Cancelled during the period, Number of warrants	0	0
Expired during the period, Number of warrants	0	0
Ending Balance	12,203,651	5,994,651
Outstanding, opening of the period, weighted average price	$ 7.41	$ 8.91
Exercised during the period, weighted average price	0	0
Issued during the period, weighted average price	0	0
Cancelled during the period, weighted average price	0	0
Expired during the period, weighted average price	0	0
Outstanding, ending of the period, weighted average price	$ 7.41	$ 8.91

Warrant Liability - Additional Information (Details)	Aug. 31, 2021 $ / shares
Level 3
Class Of Warrant Or Right [Line Items]
Estimated fair value of warrant liability per warrant	$ 9.74

Warrant Liability - Schedule of Estimated Fair Value of Warrant Liability (Details)	Aug. 31, 2021 USD ($) yr
Expected Term
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Warrant and rights measurement input \| yr	4
Warrant \| Risk-free Interest Rate \| Level 3
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Warrant and rights measurement input	0.84
Warrant \| Expected Volatility \| Level 3
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Warrant and rights measurement input	70
Warrant \| Expected Term \| Level 3
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Warrant and rights measurement input \| yr	4.05
Warrant \| Expected Dividend Yield \| Level 3
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Warrant and rights measurement input	0.0
Warrant \| Strike Price \| Level 3
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Warrant and rights measurement input \| $	5.95
Warrant \| Fair Value of Common Stock \| Level 3
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Warrant and rights measurement input \| $	13.69

Stock-Based Compensation - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended
	Aug. 31, 2021	Aug. 31, 2020	May 31, 2021
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Allocated share-based compensation expenses	$ 9,417	$ 2,850
Tilray 2018 Equity Incentive Plan and Original Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock options granted	0	0
Number of RSUs granted	1,345,158
Number of RSUs vested	0	0
Predecessor Plan \| Time-based Stock Options \| Aphria
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock options granted	0
Intrinsic values of stock options exercised	$ 430	$ 238
Fair values of stock option vested	1,797	1,723
Predecessor Plan \| Time-based and Performance-based RSU \| Aphria
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Fair values of stock option vested	12,063	$ 862
Unrecognized compensation expenses	$ 789		$ 15,111
Unrecognized stock-based compensation expense to be recognized in period, years	1 year 14 days	1 year 10 months 6 days
Accelerated fully vested	679,000

Stock-Based Compensation - Schedule of Stock-Based Activity Under EIP and Original Plan (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended	12 Months Ended
	Aug. 31, 2021	May 31, 2021
EIP Time-based Stock Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock Options, Beginning Balance	3,180,226
Shares, Exercised	(67,750)
Shares, Forfeited	(112,306)
Shares, Cancelled	(2,498)
Stock Options, Ending Balance	2,997,672	3,180,226
Weighted-average exercise price, Beginning Balance	$ 14.19
Weighted-average exercise price, Exercised	7.76
Weighted-average exercise price, Forfeited	21.40
Weighted-average exercise price, Cancelled	65.20
Weighted-average exercise price, Ending Balance	$ 14.02	$ 14.19
Weighted average remaining contractual term (years)	6 years 6 months	1 year 3 months 18 days
Aggregate intrinsic value, Beginning balance	$ 25,171
Aggregate intrinsic value, Ending balance	$ 15,843	$ 25,171
Original Plan Time-based Stock Option
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock Options, Beginning Balance	917,545
Shares, Exercised	(411,742)
Shares, Forfeited	(4,250)
Shares, Cancelled	(16,093)
Stock Options, Ending Balance	485,460	917,545
Weighted-average exercise price, Beginning Balance	$ 3.97
Weighted-average exercise price, Exercised	3.41
Weighted-average exercise price, Forfeited	4.79
Weighted-average exercise price, Cancelled	26.30
Weighted-average exercise price, Ending Balance	$ 3.69	$ 3.97
Weighted average remaining contractual term (years)	2 years 8 months 12 days	1 year 8 months 12 days
Aggregate intrinsic value, Beginning balance	$ 11,886
Aggregate intrinsic value, Ending balance	$ 4,954	$ 11,886
EIP Time-based RSU
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock Options, Beginning Balance	1,205,243
Stock options granted	981,229
Shares, Vested	(126,393)
Shares, Forfeited	(121,295)
Stock Options, Ending Balance	1,938,784	1,205,243
Weighted-average grant date fair value per share, Beginning Balance	$ 15.16
Weighted-average grant date fair value per share, Granted	14.39
Weighted-average grant date fair value per share, Vested	19.52
Weighted-average grant date fair value per share, Forfeited	16.39
Weighted-average grant date fair value per share, Ending Balance	$ 14.41	$ 15.16
Aggregate intrinsic value, Beginning balance	$ 20,091
Aggregate intrinsic value, Ending balance	$ 28,709	$ 20,091
EIP Performance-based RSU
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock options granted	1,345,158
Stock Options, Ending Balance	1,345,158
Weighted average remaining contractual term (years)	2 years 10 months 24 days
Weighted-average grant date fair value per share, Granted	$ 13.13
Weighted-average grant date fair value per share, Ending Balance	$ 13.13
Aggregate intrinsic value, Granted	$ 17,668
Aggregate intrinsic value, Ending balance	$ 17,668

Stock-Based Compensation - Schedule of Stock Option Activity (Details) - Time-based Stock Options - Predecessor Plan - Aphria - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended	12 Months Ended
	Aug. 31, 2021	May 31, 2021
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock Options, Beginning Balance	2,499,185
Shares, Granted	0
Shares, Exercised	(56,301)
Shares, Forfeited	(638)
Shares, Expired	(405,455)
Stock Options, Ending Balance	2,036,790	2,499,185
Shares, Vested and exercisable	1,821,178
Weighted-average exercise price, Beginning Balance	$ 12.48
Weighted average exercise price, Exercised	9.34
Weighted average exercise price, Forfeited	8.95
Weighted average exercise price, Expired	19.94
Weighted-average exercise price, Ending Balance	11.08	$ 12.48
Weighted average exercise price, Vested and exercisable	11.17
Weighted-average grant date fair value per share, Beginning Balance	6.51
Weighted average grant date fair value, Exercised	4.50
Weighted-average grant date fair value per share, Forfeited	4.15
Weighted average grant date fair value, Expired	9.29
Weighted-average grant date fair value per share, Ending Balance	6.02	$ 6.51
Weighted average grant date fair value, Vested and exercisable	$ 6.10
Weighted average remaining contractual term (years)	2 years 8 months 1 day	2 years 4 months 24 days
Weighted average remaining contractual term (years), Vested and exercisable	2 years 7 months 24 days
Aggregate Intrinsic Amount	$ 5,321	$ (10,472)
Aggregate Intrinsic Amount, Vested and exercisable	$ 4,588

Stock-Based Compensation - Schedule of Predecessor Plan Time-based and Performance-based RSU Activity (Details) - Predecessor Plan - Aphria - Time-based RSUs	3 Months Ended
	Aug. 31, 2021 $ / shares shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Beginning balance \| shares	2,794,972
Exercised \| shares	(1,574,381)
Forfeited \| shares	(46,171)
Ending balance \| shares	1,174,419
Weighted average grant - date fair value per share, Beginning Balance \| $ / shares	$ 6.88
Weighted average grant - date fair value per share, Exercised \| $ / shares	6.56
Weighted average grant - date fair value per share, Forfeited \| $ / shares	15.09
Weighted average grant - date fair value per share, Ending Balance \| $ / shares	$ 6.98

Accumulated Other Comprehensive Income (Loss) - Schedule of Accumulated Other Comprehensive Loss (Details) - USD ($) $ in Thousands	3 Months Ended
	Aug. 31, 2021	Aug. 31, 2020
Accumulated Other Comprehensive Income Loss [Line Items]
Beginning balance	$ 152,668
Other comprehensive loss	(101,421)	$ 1,385
Ending balance	51,247
Foreign Currency Translation Gain (Loss) [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Beginning balance	156,417
Other comprehensive loss	(100,772)
Ending balance	55,645
Unrealized Loss on Convertible Notes Receivables [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Beginning balance	(3,749)
Other comprehensive loss	(649)
Ending balance	$ (4,398)

- Definition

Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.

+ References + Details

- Definition

Amount after tax and reclassification adjustments of other comprehensive income (loss).

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 17
-URI http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 55
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

+ Details

Non-controlling Interests - Summary of Information Relating to Company's Subsidiaries (Details) - USD ($) $ in Thousands	3 Months Ended
	Aug. 31, 2021	Aug. 31, 2020	May 31, 2021
Minority Interest [Line Items]
Current assets	$ 844,618		$ 883,609
Current liabilities	(526,830)		(401,241)
Revenue	168,023	$ 117,490
Shareholders of Tilray Inc.	(41,649)	(34,343)
Other comprehensive loss	(101,421)	1,385
Shareholders of Tilray Inc.	(143,070)	(32,958)
Non-controlling Interests
Minority Interest [Line Items]
Current assets	80,531		20,765
Non-current assets	469,157		300,386
Current liabilities	(187,945)		(29,529)
Non-current liabilities	(104,516)		(76,344)
Net assets	257,227		215,278
Revenue	20,325	30,035
Total expenses (recovery)	13,280	17,436
Shareholders of Tilray Inc.	7,045	12,599
Shareholders of Tilray Inc.	7,045	12,599
Non-controlling Interests \| SH Acquisition
Minority Interest [Line Items]
Current assets	52,995
Non-current assets	170,799
Current liabilities	(170,799)
Net assets	52,995
Non-controlling Interests \| CC Pharma Nordic ApS
Minority Interest [Line Items]
Current assets	951		919
Non-current assets	132		103
Current liabilities	(1,033)		(956)
Non-current liabilities	(392)		(406)
Net assets	(343)		(340)
Total expenses (recovery)	4
Shareholders of Tilray Inc.	(4)
Shareholders of Tilray Inc.	(4)
Non-controlling Interests \| Aphria Diamond
Minority Interest [Line Items]
Current assets	26,058		19,531
Non-current assets	156,839		153,696
Current liabilities	(16,047)		(28,511)
Non-current liabilities	(80,543)		(69,332)
Net assets	86,307		75,384
Revenue	20,325	30,035
Total expenses (recovery)	13,274	17,675
Shareholders of Tilray Inc.	7,051	12,360
Shareholders of Tilray Inc.	7,051	12,360
Non-controlling Interests \| ColCanna S.A.S.
Minority Interest [Line Items]
Current assets	527		315
Non-current assets	141,387		146,587
Current liabilities	(66)		(62)
Non-current liabilities	(23,581)		(6,606)
Net assets	118,267		$ 140,234
Total expenses (recovery)	2	(239)
Shareholders of Tilray Inc.	(2)	239
Shareholders of Tilray Inc.	$ (2)	$ 239

Commitments and Contingencies - Schedule of Purchase and Other Commitments Maturities (Details) $ in Thousands	Aug. 31, 2021 USD ($)
Other Commitments [Line Items]
Total	$ 807,776
2022 (remaining nine months)	74,608
2023	98,398
2024	368,077
2025	263,236
2026	2,516
Thereafter	941
Long-term Debt Repayment
Other Commitments [Line Items]
Total	198,253
2022 (remaining nine months)	32,981
2023	78,820
2024	80,838
2025	2,157
2026	2,516
Thereafter	941
Convertible Notes, Principal and Interest
Other Commitments [Line Items]
Total	571,989
2022 (remaining nine months)	13,893
2023	13,893
2024	284,803
2025	259,400
ABG Finance Liability
Other Commitments [Line Items]
Total	6,000
2022 (remaining nine months)	1,500
2023	1,500
2024	1,500
2025	1,500
Material Purchase Obligations
Other Commitments [Line Items]
Total	29,523
2022 (remaining nine months)	24,222
2023	4,185
2024	937
2025	179
Construction Commitments
Other Commitments [Line Items]
Total	2,012
2022 (remaining nine months)	$ 2,012

Commitments and Contingencies - Additional Information (Details)	Sep. 17, 2021 shares
Subsequent Event
Other Commitments [Line Items]
Common stock issued, shares	9,817,061

Commitments and Contingencies - Summary of Future Undiscounted Payment Associated with Lease Liabilities (Details) $ in Thousands	3 Months Ended
	Aug. 31, 2021 USD ($)
Operating leases
2022 (remaining nine months)	$ 3,832
2023	4,437
2024	3,840
2025	3,321
2026	3,472
Thereafter	8,522
Total minimum lease payments	27,423
Imputed interest	(5,778)
Obligations recognized	$ 21,645
Operating Lease Liability Statement Of Financial Position [Extensible List]	tlry:OperatingLeaseLiabilityMember
Finance leases
2022 (remaining nine months)	$ 1,672
2023	7,088
2024	2,061
2025	2,122
2026	2,186
Thereafter	39,586
Total minimum lease payments	54,715
Imputed interest	(19,167)
Obligations recognized	$ 35,548
Finance Lease Liability Statement Of Financial Position [Extensible List]	tlry:FinanceLeaseLiabilityMember

Net Revenue - Additional Information (Details)	3 Months Ended
Net Revenue - Additional Information (Details)	Aug. 31, 2021 Segment
Revenues [Abstract]
Number of operating segments	4

Net Revenue - Summary of Net Revenue (Details) - USD ($) $ in Thousands	3 Months Ended
	Aug. 31, 2021	Aug. 31, 2020
Net revenue	$ 168,023	$ 117,490
Cannabis Revenue
Net revenue	89,933	67,120
Cannabis Excise Taxes
Net revenue	(19,484)	(15,918)
Net Cannabis Revenue
Net revenue	70,449	51,202
Beverage Alcohol Revenue
Net revenue	16,483
Beverage Alcohol Excise Taxes
Net revenue	(1,022)
Net Beverage Alcohol Revenue
Net revenue	15,461
Distribution Revenue
Net revenue	67,186	$ 66,288
Wellness Revenue
Net revenue	$ 14,927

- Definition

Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 924
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856

+ Details

Cost of Goods Sold - Summary of Cost of Goods Sold (Details) - USD ($) $ in Thousands	3 Months Ended
	Aug. 31, 2021	Aug. 31, 2020
Cost Of Goods And Services Sold [Abstract]
Cannabis costs	$ 40,190	$ 25,775
Beverage alcohol costs	6,662
Distribution costs	59,290	56,770
Wellness costs	10,925
Total	$ 117,068	$ 82,545

General and Administrative Expenses - Schedule of General and Administrative Expenses (Details) - USD ($) $ in Thousands	3 Months Ended
	Aug. 31, 2021	Aug. 31, 2020
General And Administrative Expense [Abstract]
Executive compensation	$ 3,090	$ 2,250
Office and general	12,769	4,421
Salaries and wages	15,311	9,343
Stock-based compensation	9,417	2,850
Insurance	4,631	3,206
Professional fees	2,713	2,935
Travel and accommodation	790	727
Rent	766	240
Total	$ 49,487	$ 25,972

Non-operating income (expense) - Schedule of Non-Operating Income (Expense) (Details) - USD ($) $ in Thousands	3 Months Ended
	Aug. 31, 2021	Aug. 31, 2020
Nonoperating Income Expense [Abstract]
Change in fair value of convertible debenture	$ 39,370	$ 340
Change in fair value of warrant liability	17,535
Foreign exchange loss	(5,724)	(16,331)
Loss on long-term investments	(1,675)	(1,120)
Gain from equity investees	1,356
Other non-operating (losses) gains, net	(2,002)	3,752
Total	$ 48,860	$ (13,359)

Financial Risk Management and Financial Instruments - Additional Information (Details) $ in Thousands	3 Months Ended
	Aug. 31, 2021 USD ($)	May 31, 2021 USD ($)
Financial Risk Management And Financial Instruments [Line Items]
Long-term debt, subject to fixed interest rates	$ 18,974	$ 20,358
Hypothetical decrease in fair value of investments	10.00%
Estimated decrease in fair values of investments upon hypothetical decrease of 10% in the prices	$ 18,641
Hypothetical increase in common stock	10.00%
Estimated increase in fair values of warrant liability upon hypothetical increase of 10% in the price of common stock	$ 6,047
Discount Rate
Financial Risk Management And Financial Instruments [Line Items]
Business combination, contingent consideration, liability, measurement input	0.05

Financial Risk Management and Financial Instruments - Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($) $ in Thousands	Aug. 31, 2021	May 31, 2021
Financial liabilities
Contingent consideration	$ 61,494	$ 60,657
Convertible debenture	611,646	667,624
Fair Value, Measurements, Recurring
Financial assets
Cash and cash equivalents	376,297	488,466
Convertible notes receivable	2,370	2,485
Long-term investments	180,907	12,185
Financial liabilities
Warrant liability	60,476	78,168
Contingent consideration	61,494	60,657
Total recurring fair value measurements	1,024,042	1,041,405
Fair Value, Measurements, Recurring \| APHA 24 Convertible Debenture
Financial liabilities
Convertible debenture	342,499	399,444
Level 1 \| Fair Value, Measurements, Recurring
Financial assets
Cash and cash equivalents	376,297	488,466
Long-term investments	7,174	9,251
Financial liabilities
Total recurring fair value measurements	383,471	497,717
Level 2 \| Fair Value, Measurements, Recurring
Financial assets
Convertible notes receivable	2,370	2,485
Long-term investments	173,733	2,934
Financial liabilities
Total recurring fair value measurements	176,103	5,419
Level 3 \| Fair Value, Measurements, Recurring
Financial liabilities
Warrant liability	60,476	78,168
Contingent consideration	61,494	60,657
Total recurring fair value measurements	464,468	538,269
Level 3 \| Fair Value, Measurements, Recurring \| APHA 24 Convertible Debenture
Financial liabilities
Convertible debenture	$ 342,499	$ 399,444

Financial Risk Management and Financial Instruments - Schedule of Balances of Assets and Liabilities Categorized Within Level 3 of Fair Value Hierarchy Measured at Fair Value on Recurring Basis (Details) - Level 3 - Fair Value, Measurements, Recurring $ in Thousands	3 Months Ended
	Aug. 31, 2021 USD ($)
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Beginning balance	$ (538,269)
Unrealized gain (loss) on fair value	73,800
Ending balance	(464,469)
APHA 24 Convertible Debenture
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Beginning balance	(399,444)
Unrealized gain (loss) on fair value	56,945
Ending balance	(342,499)
Contingent Consideration
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Beginning balance	(78,168)
Unrealized gain (loss) on fair value	17,692
Ending balance	(60,476)
Warrant Liability
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Beginning balance	(60,657)
Unrealized gain (loss) on fair value	(837)
Ending balance	$ (61,494)

Financial Risk Management and Financial Instruments - Schedule of Financial Assets and Liabilities Measurement Inputs and Valuation Techniques (Details)	3 Months Ended
	Aug. 31, 2021 yr
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Debt Instrument, Valuation Technique [Extensible Enumeration]	http://www.tilray.com/#ValuationTechniqueBlackScholesMember
Warrants and Rights Outstanding, Valuation Technique [Extensible Enumeration]	http://www.tilray.com/#ValuationTechniqueBlackScholesMember
Business Combination, Contingent Consideration, Liability, Valuation Technique [Extensible Enumeration]	us-gaap:ValuationTechniqueDiscountedCashFlowMember
Volatility [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Measurement input	0.70
Warrant and rights measurement input	0.70
Expected Term
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Measurement input	3
Warrant and rights measurement input	4
Discount Rate
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Contingent consideration	0.05
Achievement [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Contingent consideration	1.00

Segment Reporting - Additional Information (Details)	3 Months Ended
Segment Reporting - Additional Information (Details)	Aug. 31, 2021 Segment Customer	Aug. 31, 2020 Customer
Segment Reporting Information [Line Items]
Number of operating segments \| Segment	4
Number of major customers \| Customer	0	0
Customer Concentration Risk \| Revenue \| Major Customers
Segment Reporting Information [Line Items]
Concentration risk, percentage	10.00%	10.00%

Segment Reporting - Schedule of Segment Net Revenue From External Customers (Details) - USD ($) $ in Thousands	3 Months Ended
	Aug. 31, 2021	Aug. 31, 2020
Segment Reporting Information [Line Items]
Revenue from external customers	$ 168,023	$ 117,490
Cannabis Business
Segment Reporting Information [Line Items]
Revenue from external customers	70,449	51,202
Distribution Business
Segment Reporting Information [Line Items]
Revenue from external customers	67,186	$ 66,288
Beverage Alcohol Business
Segment Reporting Information [Line Items]
Revenue from external customers	15,461
Wellness Business
Segment Reporting Information [Line Items]
Revenue from external customers	$ 14,927

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 924
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856

+ Details

Segment Reporting - Schedule of Segment Gross Profit From External Customers (Details) - USD ($) $ in Thousands	3 Months Ended
	Aug. 31, 2021	Aug. 31, 2020
Segment Reporting Information [Line Items]
Total gross profit	$ 50,955	$ 34,945
Cannabis Business
Segment Reporting Information [Line Items]
Total gross profit	30,258	25,427
Distribution Business
Segment Reporting Information [Line Items]
Total gross profit	7,896	$ 9,518
Beverage Alcohol Business
Segment Reporting Information [Line Items]
Total gross profit	8,799
Wellness Business
Segment Reporting Information [Line Items]
Total gross profit	$ 4,002

- Definition

Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1,2)
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

+ Details

Segment Reporting - Summary of Channels of Cannabis Revenue (Details) - USD ($) $ in Thousands	3 Months Ended
	Aug. 31, 2021	Aug. 31, 2020
Segment Reporting Information [Line Items]
Net revenue	$ 168,023	$ 117,490
Total	168,023	117,490
Cannabis
Segment Reporting Information [Line Items]
Less excise taxes	(19,484)	(15,918)
Total	70,449	51,202
Cannabis \| Revenue from Medical Cannabis Products
Segment Reporting Information [Line Items]
Net revenue	8,374	6,380
Cannabis \| Revenue from Adult-use Cannabis Products
Segment Reporting Information [Line Items]
Net revenue	69,593	56,948
Cannabis \| Revenue from Wholesale Cannabis Products
Segment Reporting Information [Line Items]
Net revenue	1,700	$ 3,792
Cannabis \| Revenue from International Cannabis Products
Segment Reporting Information [Line Items]
Net revenue	$ 10,266

Segment Reporting - Schedule of Geographic Net Revenue (Details) - USD ($) $ in Thousands	3 Months Ended
	Aug. 31, 2021	Aug. 31, 2020
Segment Reporting Information [Line Items]
Total net revenue	$ 168,023	$ 117,490
North America
Segment Reporting Information [Line Items]
Total net revenue	90,543	51,192
EMEA
Segment Reporting Information [Line Items]
Total net revenue	76,009	65,077
Latin America
Segment Reporting Information [Line Items]
Total net revenue	$ 1,471	$ 1,221

- Definition

+ References

+ Details

Segment Reporting - Schedule of Geographic Capital Assets (Details) - USD ($) $ in Thousands	Aug. 31, 2021	May 31, 2021
Segment Reporting Information [Line Items]
Capital assets	$ 621,339	$ 650,698
North America
Segment Reporting Information [Line Items]
Capital assets	477,278	504,575
EMEA
Segment Reporting Information [Line Items]
Capital assets	139,958	140,838
Latin America
Segment Reporting Information [Line Items]
Capital assets	$ 4,103	$ 5,285